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Summary 
This document presents the Consolidated Standards Of Reporting Trials (CONSORT) extension for the stepped-wedge 
cluster randomised trial (SW-CRT). The SW-CRT involves randomisation of clusters to different sequences that 
dictate the order (or timing) at which each cluster will switch to the intervention condition. The development of this 
statement was motivated by the unique design characteristics of this study design, including the need to allow for 
time effects and because the design is increasingly being used. The guideline was developed using a Delphi survey 
and consensus meeting; and is informed by the CONSORT statements for individually and cluster randomised trials. 
Reporting items along with explanations and examples are provided. We include a glossary of terms, and explore the 
key properties of the SW-CRT which require special consideration in their reporting.  
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Introduction 
The CONSORT (Consolidated Standards Of Reporting Trials) statement, initially published in 1996 and updated in 
2001 and 2010, outlines essential items to be reported in a parallel arm individually randomised trial [Begg 1996; 
Rennie 2001; Schulz 2010]. The CONSORT extension for cluster randomised trials, initially published in 2004 and 
updated in 2012, extended this guidance for trials in which groups of individuals (clusters – for a full glossary of 
terms see Table 1) are randomised to different treatment conditions [Campbell 2004; Campbell 2012]. In recent 
years, a novel type of cluster randomized design - the stepped-wedge cluster randomised trial (SW-CRT) - has 
become increasingly popular [Brown 2006; Mdege 2011, Martin 2017]. The SW-CRT involves randomisation of 
clusters to different sequences. These sequences dictate the order (or timing) with which each cluster will switch to 
the intervention condition.  
The basic components of the design, as well as illustrative examples of studies which have used this design, have 
been described previously [Hemming 2015]. The unit of randomisation in these trials is the cluster with clusters (or 
groups of clusters) allocated to different sequences (as opposed to different “arms” in a parallel trial). These 
sequences specify the number of time periods spent in the control condition and the number of time periods in the 
intervention condition. In Figure 1, for example, there are four groups of clusters allocated to four different 
sequences. Each cluster contributes data to the analysis from each measurement period. In the example in Figure 1 
there are five measurement periods. The point at which a cluster switches to the intervention condition is called a 
“step”. Sometimes a transition period is built into the design, during which the intervention is implemented in the 
cluster.  
This design has numerous methodological complexities, including potential confounding with time [Hemming 2017]; 
changes in correlation structures over time [Girling 2016; Hooper 2016; Kasza 2017]; the possibility of within cluster 
contamination over time [Copas 2015]; the possibility of time varying treatment effects [Davey 2015, Hemming 
2017]; and different design variations [Prost 2015; Hargreaves 2015], all of which increase the complexity of 
reporting [Hemming 2015]. Perhaps unsurprisingly, systematic reviews examining the adequacy of reporting of SW-
CRTs have revealed numerous inadequacies, including absence of essential details of the design, inconsistent use of 
terminology [Brown 2006; Mdege 2011; Martin 2016; Grayling 2017; Taljaard 2017]; frequent lack of clarity in 
reporting of adjustment for time effects [Hemming 2017; Martin 2017]; as well as frequent failure to report ethical 
review and trial registration [Taljaard 2017]. These findings suggest there is a need for a specific reporting guideline 
for this trial design. Here we report the results of a consensus process to develop an extension to the CONSORT 
statement for use with SW-CRTs. The ultimate goal of this extension is to improve the standards of reporting of this 
important and increasingly used research design. 
Scope of this statement 
This reporting statement should be followed when reporting results from any SW-CRT. In line with other CONSORT 
statements this guideline includes the minimum set of items that should be reported; it is not intended to be a 
comprehensive list of all possible items that could be reported. 
A wide variety of terms have been used to describe aspects of the SW-CRT design. For the purpose of this reporting 
statement, the key components of the design are defined in Figure 1 and a glossary of terms is provided in Table 1. 
Generally, SW-CRTs have a minimum of three sequences. Trials with two sequences and three periods, for example, 
a two-arm cluster randomised trial in which both arms are initially observed under the control condition and in 
addition, the control arm adopts the intervention during a third measurement period might also technically be 
considered a SW-CRT. The statement was developed for comparisons of two treatment conditions. So as to take a 
broader perspective on the range of designs that can be included, we are not restricting our definition to designs 
with all clusters initiating in the control condition and ending up in the intervention condition [Hooper 2016].  
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Extending the CONSORT statement to SW-CRTs  
We developed this extension using methods recommended for developing reporting guidelines [Moher 2010]. We 
registered our protocol on the EQUATOR website in July 2015 [Hemming 2015c] and identified relevant and related 
reporting guidelines. We conducted several systematic reviews of published SW-CRTs examining aspects of reporting 
and methodological conduct and undertook a consensus process.  
Results from systematic reviews examining SW-CRT methods and reporting  
We conducted several systematic reviews in advance of the consensus process [Martin 2016; Taljaard 2017; Grayling 
2017; Martin 2017]. Martin et al. (2016) found that the SW-CRT is increasingly being used and that the majority of 
trials are conducted in advanced economies and in healthcare settings; although a significant minority are conducted 
in lower middle income settings; with most trials having less than 20 clusters and a smaller number of time periods 
[Martin 2016].  
Reviews of the quality of reporting of sample size and analysis methods revealed incomplete or inadequate reporting 
overall, and specifically, lack of reporting of how time effects and extended correlation structures were incorporated 
both at the design and analysis stages [Davey 2015; Martin 2016; Grayling 2017; Martin 2017]. Reviews of the ethical 
conduct and reporting revealed that many SW-CRTs do not report research ethics review; do not clearly identify 
from whom and for what consent was obtained; and a significant number do not pre-register with a trial registration 
database [Taljaard 2017]. Reviews of the methodological literature have identified several key aspects of the SW-CRT 
which are associated with bias [Barker 2016; Martin 2017]. Clear reporting of these aspects is essential to facilitate 
interpretation of trial results in published reports.  
Firstly, time is a potential confounder in a SW-CRT and requires special consideration both at the design and analysis 
stage [Hughes 2007; Hemming 2017]. Secondly, as the SW-CRT is a longitudinal and clustered study, correlation 
structures are more complex than those of a parallel CRT carried out at a single cross-section in time [Hooper 2016]. 
Thirdly, some SW-CRTs are at risk of within-cluster contamination. Within-cluster contamination can arise either 
when outcomes in the intervention condition are obtained from participants who are yet to be exposed to the 
intervention, or alternatively, when outcome assessments in the control condition are from participants already 
exposed to the intervention [Copas 2015]. Contamination arising from observations yet to be fully exposed to the 
intervention condition can be allowed for by building in transition periods into the design; or by modelling these 
effects (referred to as lag effects) [Hughes 2015]. Interactions between time and treatment can also arise. These 
time varying effects are more likely to arise when the intervention is not continuously delivered, does not create a 
permanent change, or where its impact might wane or grow over time [Davey 2015].  
These complexities differ according to the many different ways that a SW-CRT can be conducted, including whether 
the same or different participants are repeatedly assessed, whether participants are continuously recruited and the 
duration of their exposure, and whether a complete enumeration of the cluster is taken [Hemming 2015; Copas 
2015]. With practical and ethical considerations also in play, the adoption of this design requires careful justification 
[Prost 2015; Doussau 2016]. A summary of key methodological issues which need extra consideration when 
reporting a SW-CRT is presented in Table 2.  
Consensus process 
Members of the working group (KH, MT, JEM, AF, CW, JG) identified items from the original CONSORT statement 
which required modification; considered whether the modification used in the cluster extension was appropriate; 
and if not, proposed a modified version for the item. In a modified Delphi process (December 2016), we invited 64 
subject experts to consider, rate and comment on the proposed modifications of whom 42 completed the survey. 
We summarised responses from the survey and circulated a second draft of the proposed modifications in advance 
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of a one-day consensus meeting (Liverpool May 2017). The CONSORT stepped-wedge consensus group (20 people in 
total all listed as authors of this statement) consisted of members of the working group and those with expertise in 
trial design, journal editors (BMJ Open, Trials, Clinical Trials, and BMJ Quality and Safety Improvement), ethicists, 
statisticians, methodologists, and developers of reporting guidelines (cluster trials, pilot and feasibility trials and 
equity trials). At the meeting, proposed wording, examples and elaboration text were discussed and amended. The 
proposed final wording was then circulated and final comments incorporated. 
 
The CONSORT extension for Stepped-Wedge Cluster Randomised Trials  
A checklist detailing the 26 items to be reported in the publication of a SW-CRT is presented in Table 3. Some items 
have not been modified from the original CONSORT statement, some are modified, and some are new. Similar to the 
CONSORT extension for cluster trials, Item 10 (Implementation of randomisation) has been replaced by Items 10a, 
10b and 10c. In recognition of the under-reporting of key ethical aspects of these trials, a new item on Research 
Ethics Review has been added as Item 26 (as was added to the CONSORT extension for pilot and feasibility studies 
[Eldridge 2016]). For ease of interpretation in the elaboration that follows, we provide the original CONSORT 
wording, the wording of the CONSORT extension for cluster randomised trials, as well as the wording for the SW-CRT 
extension. Table 4 summarises key changes to the original CONSORT statement and substantial deviations from the 
CONSORT extension for cluster randomised trials. We have provided examples and explanations for most items. 
Where the item has not been modified or the modification is only minor, readers are referred to the original 
statements for full explanation and elaboration [Schulz 2010; Campbell 2012]. For some items, which have not been 
modified, an example or explanation has been provided where this item raises specific nuances under the SW-CRT. 
Given differences in terminology used to describe the SW-CRT and the significant number of modified items, the 
items in this statement have been written in such a way so as to replace the original CONSORT items; and therefore, 
should not be considered extensions to the original items.  
Title and abstract 
Item 1a Title 
Standard CONSORT item: Identification as a randomised trial in the title. 
CONSORT cluster extension: Identification as a cluster randomised trial in the title. 
Extension for SW-CRTs: Identification as a stepped-wedge cluster randomised trial in the title. 
 
Example: “The Devon Active Villages Evaluation (DAVE) trial of a community-level physical activity intervention in 
rural south-west England: a stepped wedge cluster randomised controlled trial.” [DAVE Trial] 
 
Explanation: One reason for including the type of study design in the title is to facilitate accurate identification of 
relevant studies in systematic reviews. A wide variety of different terminology is currently used to describe the SW-
CRT. These include the "multiple-period baseline design" and the "wait list design" (although not every multiple-
period baseline design and wait list design will be a SW-CRT). Adoption of a single term will improve the 
identification of these studies and differentiate studies which are not SW-CRTs. Reporting of parallel cluster 
randomised trials (CRT) improved with the adoption of the single term “cluster” rather than the mix of terms (such 
as “group randomised” or “field trial”) [Ivers 2011]. It can also be useful to report any trial acronym in the title, to aid 
future searches for the study.  
Item 1b: Abstract 
Standard CONSORT item: Structured summary of trial design, methods, results, and conclusions (for specific 
guidance see CONSORT for abstracts). 
Page 7 of 90
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
7 
 
CONSORT cluster extension: Abstract See Table (not shown).  
Extension for SW-CRTs: Structured summary of trial design, methods, results, and conclusions (Table 5). 
 
For the same rationale as provided in the other CONSORT statements, clear reporting of the trial’s objectives, design, 
methods, main results and conclusions in the abstract is crucial. The primary reason for this is that many readers will 
base their assessment of the trial from the information available in the abstract [Hopewell 2008]. A review assessing 
the quality of reporting of abstracts from fully published SW-CRT revealed incomplete reporting of important details 
[Wang 2017]. A set of items to be reported as a minimum in an abstract of a SW-CRT is included in Table 5. Of some 
note, the Items recommended to be reported in the abstract results section do not include the summary measures 
of the outcome under intervention and control conditions, so as to avoid misattributing the unadjusted difference to 
the treatment effect. A worked example of an abstract according to this template is provided (Table S1, Long-live 
Mothers Trial). 
Introduction  
Item 2a: Background 
Standard CONSORT: Scientific background and explanation of rationale. 
CONSORT cluster extension: Rationale for using a cluster design 
Extension for SW-CRTs: Scientific background. Rationale for using a cluster design and rationale for using a 
stepped-wedge design. 
 
Example 1 (Scientific background): “In 2008, the World Health Organization (WHO) introduced the Surgical Safety 
Checklist (SSC) designed to improve consistency of care. The pilot pre-/post evaluation of the WHO SSC across 8 
countries worldwide, which found reduced morbidity and mortality after SSC implementation, constituted the 
first scientific evidence of the WHO SSC effects. A number of subsequent studies to date have reported improved 
patient outcomes with use of checklists. Furthermore, checklists have also been shown to improve 
communication, preparedness, teamwork, and safety attitudes—findings that have been corroborated by a 
recent systematic review. Although checklists are becoming a standard of care in surgery, the strength of the 
available evidence has been criticized as being low because of (i) predominantly pre /post implementation 
designs without controls; (ii) lack of evidence on effect on length of stay; and (iii) lack of evidence on any 
associated cost savings. Randomized controlled trials (RCTs) are required….” [Surgical Checklist Trial] 
 
Example 2 (Rationale for cluster randomisation and stepped-wedge design): “A stepped wedge cluster 
randomised controlled design was chosen following piloting to facilitate roll out of the intervention, …, and 
prevent contamination and disappointment effects in hospitals not randomised to the intervention.” [FIT Trial] 
 
Explanation: The need for any randomised evaluation of an intervention, whether randomising clusters or individuals 
should be justified. This justification should make reference to the best available evidence for similar interventions. 
Reasons why current evidence is lacking should be articulated (as in Example 1).  
As with any trial design, key aspects of the design should be justified. In the SW-CRT, this justification includes the 
use of cluster randomisation, the need to roll out the intervention to all clusters (where this is the case), and the 
need for staggered roll-out of the intervention [Hargreaves 2015]. Justifying cluster randomisation is important 
because cluster randomisation increases the sample size and this, in turn might expose more participants to 
interventions of unknown effectiveness. Justifying the need for a staggered roll-out of the intervention using a SW-
CRT, as opposed to a simple parallel arm implementation, is important because the SW-CRT is more complicated in 
its design, analysis, and implementation than the parallel CRT. Risks of bias in the SW-CRT may be higher than in a 
parallel CRT. For example, secular trends may be of concern in a SW-CRT, but not in a parallel design [Hemming 
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2017]. Risks of bias arising from identification and recruitment of participants may also be higher because in a SW-
CRT it may be more difficult to blind people recruiting participants to the cluster’s allocation status. The design is 
consequently viewed by some as potentially providing a lower level of evidence compared to the parallel CRT 
[Mdege 2011; Kotz 2012; Haines 2017]).  
Some possible justifications for adopting the stepped-wedge design include that the intervention will be rolled out 
regardless of the research study [Prost 2015], availability of an inadequate number of clusters to achieve the target 
power in a parallel design [Hemming 2016], to increase statistical efficiency [Lawrie 2015; Girling 2016; Zhan 2017], 
or to facilitate recruitment when engagement of clusters is only forthcoming on some promise of the intervention 
(as in Example 2).  
Although staggering the roll-out may appeal to researchers with limited resources for delivering the intervention 
simultaneously, this is not in itself a legitimate argument for a SW-CRT [Hemming 2015b]. Providing the intervention 
to all clusters might also increase the duration of the study (due to the staggering of the roll-out) and will possibly 
increase the number of clusters (and patients) exposed to the intervention (due to all clusters receiving the 
intervention). For these reasons, justifying the need to expose all clusters (where this is the case) to the intervention 
is important. The cluster cross-over design is a more statistically efficient design than the SW-CRT and it might 
therefore be important to justify why a unidirectional cross-over design has been chosen. However, in practice the 
use of the cluster cross-over design is restricted to interventions that can be withdrawn from use, and this largely 
depends on the type of intervention being evaluated.  
Item 2b: Objective 
Standard CONSORT item: Specific objectives or hypotheses. 
CONSORT cluster extension: Whether objectives pertain to the cluster level, the individual participant level or 
both. 
Extension for SW-CRTs: Specific objectives or hypotheses.  
 
Example: “We report a stepped wedge cluster RCT aimed to evaluate the impact of the WHO SSC (World Health 
Organisation Surgical Safety Checklist) on morbidity, mortality, and length of hospital stay (LOS). We 
hypothesized a reduction of 30 days' in-hospital morbidity and mortality and subsequent LOS post-Checklist 
implementation.” [Surgical Checklist Trial] 
 
Explanation: Having a clear and succinct set of objectives can help summarise the overarching aims of the study. 
Specification of the objectives gives clarity about the anticipated effects of the intervention being evaluated (as in 
Example). Sometimes these effects will be anticipated to be on process outcomes (e.g. systems changes, clinician 
performance), particularly in trials which target health care providers; other times the intervention might target 
patients and anticipate effects on clinical outcomes. One specific objective which can be of interest in a SW-CRT is to 
evaluate the effect of the intervention by timing of implementation (e.g. does the effect of the intervention change 
as the intervention is perhaps refined over time) or time since intervention implementation (e.g. does the 
intervention create a permanent effect). Also of relevance is whether the study is to show superiority of the 
intervention condition, non-inferiority or equivalence. For non-inferiority or equivalence authors should also ensure 
reporting according to the CONSORT extension for non-inferiority and equivalence studies [Piaggio 2012].   
Methods: Trial design 
Item 3a: Trial design 
Standard CONSORT item: Description of trial design (such as parallel, factorial) including allocation ratio. 
CONSORT cluster extension: Definition of cluster and description of how the design features apply to the clusters. 
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Extension for SW-CRTs: Description and diagram of trial design including definition of cluster, number of 
sequences, number of clusters randomised to each sequence, number of periods, duration of time between each 
step, and whether the participants assessed in different periods are the same people, different people, or a 
mixture.  
 
Example 1: “During the DAVE study, the intervention will be rolled out sequentially to 128 rural villages (clusters) 
over four time periods. The evaluation will consist of data collection at five fixed time points (baseline and 
following each of the four intervention periods)… The intervention will be fully implemented by the end of the 
trial, with all 128 villages receiving the intervention: 22 first receiving the intervention at period 2, 36 at period 3, 
35 at period 4, and 35 at period 5.” [Dave Trial Protocol, Figure S1] 
 
Example 2: This study will use a closed cohort stepped wedge cluster randomised design, which involves a 
sequential crossover of clusters from the control to the intervention arm, so that every cluster begins in the 
control condition and eventually receives the intervention, with the order of crossover randomly determined. The 
study will be conducted in four rural villages…At the start of the study period, baseline (T0) demographic and 
health data will be collected from each consenting household and baseline hygiene education will be provided. 
…The second (T1) health survey will start 4 weeks after the initiation of piped untreated river water supply to 
evaluate the impact of hygiene education combined with improved water quantity compared with baseline (T0). 
RBF-treated water (intervention arm) will then be sequentially introduced to each village in random order at 12-
week intervals (T2–T5), with health surveys performed 4 weeks after the implementation of the intervention to 
assess the additional effects of improved water quality [Riverbank Filtration Trial, Figure 2] 
 
Explanation: The specific details of the design of the SW-CRT have implications for the type of analysis and sample 
size calculations required.  
Information on the number of sequences and the number of clusters randomised to each sequence is the core of the 
study design and so should be reported. The number of time periods will often (but not always) be one more than 
the number of steps (as in Example 1). Definition of cluster (as clearly reported in Example 1) and duration of time 
periods are also crucial. The duration of the first and last periods can sometimes differ from other periods; if so, this 
should be reported. The number of clusters allocated to each sequence may vary and, if so, this should be reported.  
Information on whether the measurements taken in the different time periods are from the same individuals or 
different individuals is important for both sample size and analysis. In an open cohort design, participants are 
repeatedly assessed over series of measurement points and participants can join and leave the cohort; in a closed 
cohort design, new participants cannot join the study; in a cross-sectional design, different participants are assessed 
at each measurement occasion. Measurements can also take place at one point in time in each period, or can be 
continuous throughout the period. This issue is covered in more detail under Item 6a (assessments of outcomes). 
A diagram of the trial design can efficiently communicate the details. Key points to depict in the design diagram are 
the timing of the interventions (Item 3a) and the timing of the data collection (Item 6a). In the Riverbank Filtration 
Trial, key information about the design was reported in a diagram (Figure 2) and the main text (Example 2).   
Item 3b: Changes to trial design 
Standard CONSORT item: Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons. 
CONSORT cluster extension: No modification suggested.  
Extension for SW-CRTs: Important changes to methods after trial commencement (such as eligibility criteria), with 
reasons. 
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Example: “…delayed Research and Development registration shortened the baseline pre-randomisation phase 
from twelve months to nine in the first hospitals randomised to the intervention.”[FIT Trial] 
 
Explanation: Changes to key features of the design can have important implications for the interpretation of results. 
Some changes or deviations may be inevitable. Potential changes in the SW-CRT include modification to the duration 
between steps (perhaps because of study set up delays as in Example). The timing of any changes is important as 
they may affect some observations / clusters and not others.  
Methods: Participants 
Item 4a: Participants 
Standard CONSORT item: Eligibility criteria for participants. 
CONSORT cluster extension: Eligibility criteria for clusters.  
Extension for SW-CRTs: Eligibility criteria for clusters and participants.  
 
Example: “Inclusion criteria: Institution level: At least two units of one (from each) nursing home must participate 
in the study, from which at least 30 residents with dementia can be recruited. The care of the residents must 
predominantly take place in the respective unit. Resident level: Criteria for inclusion are informed consent 
obtained from people with dementia or their legal representative; diagnosis of dementia based on the medical 
diagnosis in the charts and a FAST score > 1); residence for at least 14 days in the unit. Staff level: All of the 
nursing staff working in one of the two participating wards of the nursing home must provide their informed 
consent.” [FallDem Trial] 
 
Explanation: The SW-CRT is a type of cluster randomised trial and as such, has inclusion and exclusion criteria for 
both clusters and participants. Furthermore there may be multiple levels of participants. For example, clusters may 
be general practices that include cluster-level participants (e.g. general practitioners) and individual-level 
participants (e.g. patients). So, in some trials, there may be multiple levels at which inclusion and exclusion criteria 
apply (as in the Example). Reporting of eligibility criteria is important so that readers can infer how typical or atypical 
the clusters and participants are of the population at large [Zwarenstein 2008].  
Item 4b: Setting 
Standard CONSORT item: Settings and locations where the data were collected. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Settings and locations where the data were collected. 
 
Readers are referred to the CONSORT statement and its extension to CRTs for examples and explanation [Schulz 
2010, Campbell 2012].  
Methods: Intervention 
Item 5: Intervention 
Standard CONSORT item: The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered. 
CONSORT cluster extension: Whether interventions pertain to the cluster level, the individual participant level or 
both. 
Extension for SW-CRTs: The intervention and control conditions with sufficient details to allow replication, 
including whether the intervention was maintained or repeated, and whether it was delivered at the level of the 
cluster, the individual, or both.  
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Example 1 (Description of the intervention condition): “The intervention involves three key modes of delivery: 
verbally via reception staff, in paper form with a pamphlet, and electronically via a secure, internet-enabled 
tablet (see Table (not provided) for overview of intervention). First, reception staff will verify the organ donor 
registration status of patients upon their arrival at the clinic on the provincial health card that patients must 
provide to receive healthcare services from their family physician. As reception staff already request a patient’s 
health card during their visit, this step is designed to fit within existing work routines rather than increasing any 
workload. Reception staff will provide patients that have not yet registered with an educational pamphlet 
including a photo and signature of the physicians in the office and office logos and include messages that directly 
address identified barriers to donor registration. Second, internet-enabled tablets will be provided in each waiting 
room to give patients the immediate opportunity to register for organ donation online via a secure provincial 
website. The location of the materials will be tailored according to the family physician office’s preferences.” 
(further details provided in paper) [RegisterNow-1 Trial] 
 
Example 2 (Description of control condition): “If the participant’s medical centre is in the control phase, they will 
receive usual care. In Australia, usual care would mean the patient would consult their GP as per normal 
standards for that practice for a patient discharged from hospital. There will be no pharmacist in the medical 
centre during the control phase. Medication liaison in the form of a discharge medication record may be provided 
to patients on discharge from hospital and may be included in the hospital discharge summary to the GP.” 
[REMAIN Trial Protocol] 
 
Example 3 (Unit of delivery is individual): “The intervention comprised a therapeutic dose of AQ (10 mg/kg/day 
for 3 days) combined with one dose of SP on the first day (25mg sulfamethoxypirazyne and 1.25mg 
pyrimethamine per kg in 2008, 25mg sulfadoxine, 1.25mg pyrimethamine in 2009–10) administered once per 
month for the last three months of the malaria transmission season (September-November).” [SMC Trial] 
 
Example 4 (Continuously delivered intervention): “It (the intervention) comprised bedside placement of alcohol 
hand-rub, posters and patient empowerment materials encouraging healthcare workers to clean their hands, plus 
audit and feedback of hand-hygiene compliance at least once every 6 months.” [FIT Trial] 
 
Explanation: Clear reporting of the intervention is essential to allow replication and implementation of successful 
interventions (Example 1). For interventions demonstrated to have little evidence of benefit, reporting of sufficient 
detail of the intervention helps to avoid evaluating the same intervention again or to identify what aspects of the 
intervention could be modified. This is especially important for complex interventions – a common type of 
intervention evaluated in SW-CRTs. We recommend reporting details of the intervention as per the TiDierR guideline 
[Hoffmann 2014].  As per the original CONSORT statement, it is important to describe all treatment conditions being 
compared. In SW-CRTs the comparator is often "usual care" which should be described in sufficient detail (Example 
2). The control condition should be described in a similar level of detail to the intervention condition [Zwarenstein 
2008].  
Information on whether the intervention is delivered at the level of the cluster or individual (or perhaps both) is 
important as it allows identification of whether individuals can avoid the intervention. For example, an intervention 
which is delivered at the level of the cluster will often mean that it is delivered to all individuals within that cluster 
(Example 1). In the SMC Trial the intervention was delivered directly to the individual (Example 3). This information is 
also important as it can inform the degree of penetration of the intervention and it can also be helpful in eliciting 
what consent procedures should be in place (Items 10c and 26).  
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In a SW-CRT it is important to be clear about whether the intervention is expected to create an effect that is 
expected to be immediate (or delayed); and whether the anticipated effects of the intervention are expected to be 
sustained. This is important because the observations contributing to the analysis will consist of a mixture of 
observations collected immediately after roll-out of the intervention; and observations collected some time post 
roll-out.  
The effect of any intervention can be delayed; for example, due to a learning effect, one may need to allow for a 
delay before the effect is fully realised (this might be the case in Example 4). In these situations a transition period 
might be incorporated into the design. Furthermore the anticipated effects of the intervention might be sustained 
(in which case an intervention might be designed to have a one-off delivery, as in Example 1) or expected to decay 
(in which case an intervention might be designed to have repeated delivery, as in Example 4). In some SW-CRTs the 
exact form of the intervention may evolve over time; reporting this information allows assessment of the level of 
standardisation of the intervention across the clusters [Zwarenstein 2008]. 
In Example 1 the intervention being evaluated is formed of several components. Depending on the exact nature of 
the intervention, there may be a delay before any anticipated effect is realised. The effects of some components 
may also wane through familiarity. Furthermore some components of an intervention might be continuously 
delivered (i.e. provision of pamphlets) whereas some components might be delivered just once (i.e. educational 
components). In Example 4 the educational component of the intervention is re-enforced and so its anticipated 
effect is less likely to decay.  
Methods: Outcomes 
Item 6a: Outcomes 
Standard CONSORT item: Completely defined pre-specified primary and secondary outcome measures, including 
how and when they were assessed. 
CONSORT cluster extension: Whether outcome measures pertain to the cluster level, the individual participant 
level or both. 
Extension for SW-CRTs: Completely defined pre-specified primary and secondary outcome measures, including 
how and when they were assessed.  
 
Example 1 (Pre-specified outcomes): “The primary outcome of the study is a 7-day period prevalence of diarrhoea 
among villagers of all ages. Secondary outcomes include a 7-day period prevalence of other hygiene-related 
illnesses (respiratory and skin infections), reported changes in hygiene practices, household water usage and 
water supply preference.” [Riverbank Filtration Trial] 
 
Example 2 (Cross-sectional sampling): “Data collection for the evaluation took the form of a postal survey 
conducted at five fixed time points: baseline (in the month prior to commencement of the first intervention 
period) and within a week of the end of each of the four intervention periods. A repeated cross-sectional design 
was employed, in which a random sample of households within each cluster was selected to receive the survey at 
each period.” [DAVE Trial] 
 
Example 3 (Cohort design): “All household members will be eligible for inclusion in the study, regardless of age. 
…Each household will have the option to participate in up to five subsequent surveys…Outcomes will be 
measured at each of the six survey visits.” [Riverbank Filtration Trial] 
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Example 4 (Transition period): “A 1-month transition phase is included where the medical centre is not 
considered as being in control or intervention and does not contribute to analysis. This transition period allows 
for the time it takes to embed the intervention into a medical centre.” [REMAIN Trial] 
 
Example 5 (Time to assessment and source of data): “Participants will be followed up to 12 months from day of 
hospital discharge. This will be done through collection of routine data from the hospital and medical centre. 
Demographics and reason for admission at enrolment and subsequent admissions in the 12-month follow-up will 
be collected through participant hospital records…Medical centre records will be used to identify whether a 
discharge treatment plan was received and the timeliness and number of GP visits during the 12-month follow-up 
period for each participant.” 
 
Explanation: All outcomes should be completely defined. This should include the pre-specified primary outcome and 
all secondary outcome measures (Example 1). It is also important to report clearly how and when these 
measurements were obtained. 
SW-CRTs make a series of measurements over time within each cluster. These measurements could be on different 
participants in each period (i.e. cross-sectional design) as in Example 2; the same participants (i.e. cohort design) as 
in Example 3; or a mixture, and this will inform the method of analysis and has implications for sample size 
calculations. Data are rarely collected at the level of the cluster, but knowledge of whether outcomes in each period 
are at the cluster level (either because of true cluster level outcomes or because of the availability of aggregated 
data only) or individual level has implications for the method of analysis. 
It should be reported whether outcomes are collected at discrete points in time common to all participants (e.g. a 
survey implemented at several discrete points in time as in Example 3), or at time points specific to each participant 
(e.g. as they leave hospital as in Example 5). The timing of measurements has implications for the choice of analysis. 
For example, if the outcomes are collected at discrete time points (as in Example 3), then time effects can be 
included as categorical effects; whereas if the outcomes are collected continuously (for example as would be the 
case in a SW-CRT where the outcome was routinely collected mortality data), then time effects could potentially be 
modelled using parametric or semi-parametric forms.  
The reporting of the timing of data collection should also note whether there were periods in which outcomes were 
not ascertained, for example transition periods immediately after the intervention was rolled out, to allow time for 
the intervention to realise its full impact (as in Example 4).  
In individually and cluster randomised parallel trials outcomes are often assessed at multiple time points (for 
example 6 and 12 months post randomisation) and it is important to pre-specify the primary follow-up time of 
interest. This might also be the case in SW-CRTs. Sometimes the outcome assessments will extend beyond the actual 
study dates. For example, a trial might roll-out the intervention to clusters over a four year period and the primary 
follow-up time might be 30 years later [Shimakawa 2014]. Clear reporting on the timing of follow-up assessments (as 
in Example 5) also allows assessment of whether all observations collected under the intervention condition were 
fully exposed to the intervention, and whether any observations collected under the control condition might have 
been contaminated by the intervention.  
Reporting whether data were collected from routine sources or purposively collected can help ascertain the risk of 
bias (e.g. from measurement of the outcome) and identify who are the human research participants (see Item 26). 
SW-CRTs are often implemented in real-world settings and, as such, may rely on routinely collected outcome data 
(Example 5). Reporting of whether the data collection procedures changed over time is important given the 
imbalance over time with respect to intervention conditions [Shadish 2002]. It is also important to report any 
measures which can allow assessment of the reliability and validity of routinely collected data.  
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Item 6b: Changes to outcomes 
Standard CONSORT item: Any changes to trial outcomes after the trial commenced, with reasons. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Any changes to trial outcomes after the trial commenced, with reasons. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Methods: Sample size 
Item 7a: Sample size 
Standard CONSORT item: How sample size was determined. 
CONSORT cluster extension: Method of calculation, number of clusters(s) (and whether equal or unequal cluster 
sizes are assumed), cluster size, a coefficient of intra-cluster correlation (ICC or k), and an indication of its 
uncertainty. 
Extension for SW-CRTs: How sample size was determined. Method of calculation and relevant parameters with 
sufficient detail so the calculation can be replicated (Table 6). Assumptions made about correlations between 
outcomes of participants from the same cluster.  
 
Example 1 (Sample size): “We would consider an absolute increase of 10% in the proportion of patients who are 
registered organ donors at 7 days post-encounter to be both clinically important and feasible. Our sample size of 
6 clusters (10,500 patients in total) achieves 80% power to detect this difference assuming a control proportion of 
0.5 using a two-sided test at the 5% level of significance [Hooper 2016]. Our calculation assumes an intra cluster 
correlation coefficient of 0.06, as calculated from our previous work (19), an average of 250 patient encounters 
per site in each two-week interval, and a cluster autocorrelation coefficient of 0.8 to allow for a 20% decay in the 
strength of the correlation in repeated measures over time.(20) The percentage of registered donors in the 
control condition is conservatively assumed to be 50% to allow for a higher prevalence of registered donors in our 
participating offices than the provincial average. No adjustment is made for cluster attrition as the risk of attrition 
is low, and all outcomes will be assessed from routinely collected sources, regardless of any drop-out. Given some 
uncertainty around parameter estimates required for the stepped wedge sample size calculation, sensitivity of 
our detectable effect size to a range of alternative assumptions is presented in Table (not shown). The results 
show that across a range of control arm proportions (from 0.4 to 0.5), average cluster sizes (from 100 to 400), and 
cluster autocorrelation coefficients (from 0.8 to 0.95), our sample size of 6 practices will achieve 80% power to 
detect absolute increases between 5% and 11%.” [RegisterNow-1 Trial] 
 
Example 2 (Sample size fixed by design): “The study had a fixed sample size by design that could not be modified, 
so the power calculations did not inform any sample size targets.” [Targeted Case Finding Trial] 
 
Explanation:  
The method of calculation and all relevant parameters, used in the sample size calculation should be given. Most of 
the key items to report are listed in Table 6. These have been divided into key items which are essential and likely of 
relevance to all SW-CRTs; and those which might be considered additional or supplementary information which will 
only be of relevance to some SW-CRTs. Besides the usual effect size, significance level and power, these may include: 
the cluster size and whether account of unequal cluster sizes has been made, avoiding any ambiguity between 
cluster size per measurement period and total cluster size; a within-period intra-cluster correlation (ICC) and 
assumptions about correlations between outcomes of different participants from the same cluster in different 
periods (or other assumptions which appropriately reflect the complexity of the design); allowance for repeated 
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measurement taken from the same participants, with sufficient detail to allow the calculation to be replicated. Often 
a sensitivity analysis, looking at the effect of relaxing some of the assumptions, may be warranted.  
Specifying the method of sample size calculation [Hussey 2016; Hooper 2016], or providing access to sample size 
calculation code [Baio 2015; Hooper 2016; Hemming 2016] or programmed sample size function [Hemming 2014] 
can aid replication of the sample size (Example 1 reported they used the Hooper method). Detailed reporting of the 
sample size method will allow assessment of whether the method has allowed for all features inherent to the 
particular design (e.g. transition periods, repeated measures on the same participants). Reporting of the sample size 
calculation will likely include: number of clusters and whether equal or unequal cluster sizes are assumed, cluster 
size or cluster size per period, number of sequences, and number of clusters per sequence. Reporting of these basic 
sample size elements is poor in SW-CRTs [Martin 2016]; as is the reporting of basic elements in parallel CRTs 
[Rutterford 2015].  
For clarity it is important to distinguish between total cluster size (across all periods) and cluster sizes per period 
(Example 1). In a design which repeatedly measures the same participants it would be natural to provide the number 
of participants in each cluster and the number of repeated measurements per participant; in a design which involves 
taking repeated, discrete samples with different participants each time it would be natural to provide the number of 
participants in each cluster in each of these periods; whereas in a design where newly eligible individuals are 
recruited continuously it might be more appropriate to report the total number of participants expected in each 
cluster over the duration of recruitment. 
In a parallel CRT it is important to report the ICC (the correlation between outcomes of two individuals from the 
same cluster). The coefficient of variation of cluster rates, proportions or means has been suggested as an 
alternative parameter in sample size formulae for CRTs [Hayes 1999]. Correlation structures are more complicated in 
a SW-CRT and there may not be a single ICC, as the strength of correlation might depend additionally on the 
separation in time [Hooper 2015; Martin 2016b; Kasza 2017]. Such correlation structures could be formalised in a 
variety of ways, for example using a within-period ICC and a between-period ICC or cluster auto-correlation 
coefficient (as in Example 1) [Kasza 2017]. In SW-CRTs where the same individuals are assessed repeatedly it may 
also be important to consider correlations over time within individuals [Hooper 2016].    
An indication of the sensitivity of the sample size or power to the assumed parameter values could be provided, for 
example, by reporting sample size or power at a variety of alternative correlation values. Rationale for the assumed 
parameter values should be provided (as in Example 1).  
In randomised trials the sample size (and so consequently the number of clusters) is often based on the number 
needed to detect the target difference at a desired level of power and significance [Cook 2017]. SW-CRTs can 
sometimes have their sample size fixed by the number of clusters, participants, or both, available in a natural setting. 
Whether the sample size was fixed by factors outside of the control of the experimenters or based on the target 
difference (as conventionally is the case in a randomised controlled trial) should be reported (as in Example 2). When 
the sample size is fixed, it can be useful to report what effect size the study was powered to detect. If no power 
calculation was performed, this should be reported. Retrospective power calculations based on the results of the 
trial are of little merit [Hoenig 2001; Sculz 2010].  
Item 7b: Interim analyses 
Standard CONSORT item: When applicable, explanation of any interim analyses and stopping guidelines. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: When applicable, explanation of any interim analyses and stopping guidelines. 
 
Page 16 of 90
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
16 
 
Explanation: Interim analyses of outcomes can be used to assess harm, futility, and efficacy. Interim analyses can 
also be used to monitor recruitment and retention rates, and monitor balance across control and intervention 
conditions (where trial processes suggest that there may be a risk of differential recruitment or consent).  
The relevance of interim analyses of outcomes might be questionable in some SW-CRTs, so careful reporting of 
motivation is important. For example, if the intervention is being rolled out to all clusters within the fastest time 
frame possible, then stopping the trial early after demonstrating efficacy does not necessarily mean the intervention 
can be rolled out to the remaining clusters immediately. In some settings, SW-CRTs evaluate interventions for which 
safety concerns are likely to be minimal (although this will not always be the case). It might be of interest to consider 
stopping a SW-CRT for futility, although if there are minimal safety concerns then stopping the trial early for futility 
may also not be worthwhile. However, other important reasons for considering stopping a trial include that the trial 
itself is not successful, perhaps because clusters are failing to adhere to the randomisation schedule, because data 
for outcomes are not forthcoming, or because procedural requirements have delayed the start dates for many 
clusters [Kristunas 2017]. Dates or times at which any interim analysis will be carried out should be reported 
together with objectives of such interim analyses.  
Of note, in a SW-CRT due to the imbalanced nature of the design, interim analyses for outcomes carried out early in 
the trial will have a large imbalance between numbers of observations exposed to control and intervention 
conditions. This imbalance is likely to have power implications [Grayling 2017]; and will make a blinded interim 
analysis infeasible. The clustered nature of the data will also have implications on power and interim analyses [Zou 
2005]. Proposed methods of interim analysis should be outlined. Interim analyses of outcomes might or might not 
follow the same method of analysis planned for the main results. As with any trial, incorporation of any interim 
analyses of outcomes (where a decision is to be made about continuation of the trial) should be allowed for in power 
calculations to control for the over-all Type I error rate. 
Methods: Randomisation  
Item 8a: Sequence generation 
Standard CONSORT item: Method used to generate the random allocation sequence. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Method used to generate the random allocation to the sequences of treatments.  
 
Example: “Eligible schools were randomly assigned to one of the four sequences (3 or 4 schools per sequence) for 
time of crossover from control to intervention using a computer-generated list of random numbers.” [SBP Trial] 
 
Explanation: Random allocation in SW-CRTs takes a different form to that in parallel arm designs. Rather than each 
cluster being randomly allocated to one of two treatments, allocation is to one of several sequences which define 
the order with which clusters cross from the control condition to the intervention condition (Example). The term 
“sequence generation” in a SW-CRT therefore has a slightly different meaning to that of individually randomised 
trials. In an individually randomised trial “sequence” refers to a sequence of treatments to allocate all participants to 
either the intervention or control condition.  
Furthermore, rather than the randomisation being performed as clusters or individuals present to the trial the 
randomisation in a SW-CRT is usually done at a single point in time before the trial starts.  
Item 8b: Randomisation method 
Standard CONSORT: Type of randomisation; details of any restriction (such as blocking and block size). 
CONSORT cluster extension: Details of stratification or matching if used 
Extension for SW-CRTs: Type of randomisation; details of any constrained randomisation or stratification if used. 
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Example 1 (Unrestricted): “Nursing-home units were the unit of randomisation... RL (not involved in recruitment) 
randomly allocated units to one of five groups with computer-generated random numbers…” [Depression 
Management Trial] 
 
Example 2 (Stratification): “All schools are assigned a decile rating, which indicates the extent to which the school 
draws its students from a range of socioeconomic areas. Decile 1 schools are the 10% of schools with the highest 
proportion of students from low socioeconomic resource areas (defined according to residents' income, 
occupation, household crowding, educational qualifications and income support) and decile 10 are the 10% of 
schools with the highest proportion of students from high socioeconomic areas…. The order of switch-over is 
determined randomly for each group (decile) of clusters” [SBP Trial Protocol] 
 
Example 3 (Covariate constrained randomisation): “The randomization was conducted using a highly restricted 
randomization design. With this limited number of randomization units, selection of one sequence from the 5.4 
*10
26
 completely at random would run the risk of obtaining a sequence that is substantially unbalanced with 
respect to one or more potentially important covariates. Randomization was done using a highly restricted 
randomization design to achieve close balance with respect to clinic-level covariates including mean CD4 count, 
clinic size, average education, tuberculosis treatment levels, existence of a supervised tuberculosis therapy 
(DOTS) program and geography (reference cited to detailed methods)”. [THRio Trial Protocol] 
 
Explanation: In a SW-CRT, rather than the randomisations being done sequentially (as the patient or cluster presents 
to the trial), the randomisation is usually done at a single point in time before the trial starts. This means that 
different methods for controlling balance of cluster-level factors can be considered along with methods used in 
individually randomised trials such as stratification [Ivers 2012]. How the randomisation is restricted is known to 
have implications for analysis.  
There are two common ways in which clusters may be allocated in a SW-CRT. One is simple unrestricted allocation to 
one of several possible sequences (Example 1); another is stratified allocation with clusters divided into distinct 
strata prior to random allocation within each stratum (Example 2). For a stratified design the sequences are 
generated independently within each stratum. This essentially means that separate mini SW-CRTs are conducted in 
each stratum (Example 2). Yet another method of allocation is covariate constrained allocation which balances key 
covariate values (such as cluster size) between intervention and control conditions (Example 3) [Moulton 2007].  
Item 9: Allocation concealment 
Standard CONSORT item: Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until interventions were assigned. 
CONSORT cluster extension: Specification that allocation was based on clusters rather than individuals and 
whether allocation concealment (if any) was at the cluster level, the individual participant level or both.  
Extension for SW-CRTs: Specification that allocation was based on clusters; description of any methods used to 
conceal the allocation from the clusters until after recruitment.  
 
Example 1 (Concealment from cluster): “Once 14 medical centres have provided consent to be involved in the 
study, each enrolled medical centre will be randomised to a transition step.” [REMAIN Trial] 
 
Example 2 (Concealment of cross-over date):“The allocation sequence will only be made available to two study 
investigators (ABF and MS). Indian study investigators will be blinded to the allocation sequence with only the 
next village randomised for rollout being revealed at each intervention implementation time point. Study 
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participants will be blinded to the allocation sequence and those not yet receiving the intervention will not be 
aware of the time at which they will have the intervention implemented.” [Riverbank Filtration Trial] 
 
Explanation: In a SW-CRT clusters are allocated to a sequence of treatments, so clusters will spend time in the 
control condition until a particular date when they cross to the intervention condition. This is unlike a parallel arm 
cluster randomised trial in which clusters are allocated to treatment conditions. Randomisation of all clusters (to 
sequences) in a SW-CRT will often occur at a single point in time (as in Example 1). Randomisation could in theory 
also be performed at step-times, where one or more of the remaining clusters will be randomly selected to cross 
over just prior to the cross-over date (no examples of this have been identified). 
It is important to report any method that was used to conceal the allocation from clusters and from those individuals 
responsible for recruiting clusters, until after recruitment. Reporting of this information allows assessment of the 
potential for selection bias [Higgins 2016]. One common way of preserving allocation concealment is to perform the 
randomisation after recruitment of all clusters (as in Example 1).  
When randomisation of the clusters occurs at a single point, the cross-over date may be revealed immediately to 
each cluster, or revealed sequentially to the clusters as they approach the time of cross-over (as in Example 2). 
Reporting when clusters were told of their cross-over date allows assessment of potential biases. For example, when 
clusters are informed of their date of cross-over at the beginning of the trial, some clusters (e.g., those randomized 
to cross over later) may drop-out, leading to differential attrition; yet at the same time a public randomisation at the 
start of the trial may also prevent subversion of the randomisation process [Higgins 2016]. Knowledge of when a 
cluster is crossing over could lead to other biases, for example, if individuals within a cluster are aware of the 
impending cross-over, they may defer enrolling participants into the trial to ensure they receive the intervention.  
Full transparency of reporting of the blinding throughout the trial, including the randomisation process, is best 
reported using a timeline diagram [Caille 2016].  
Methods: Implementation of randomisation  
As with a parallel CRT, it is important that all steps in the implementation of the randomisation process are clearly 
described. It is important that this information on the allocation and recruitment process is described for both 
clusters and participants. Information on the allocation and enrolment of the clusters is described in Item 10a and 
corresponding information for participants in Item 10b. Enrolment of participants is closely linked to the consent 
process (for example, differential consent processes can have implications for selective recruitment). Therefore, 
following the cluster CONSORT extension, Item 10c describes the consent processes.  
Of note, we use the term “selection bias” to refer to any process by which there is differential inclusion of 
participants in the treatment conditions being compared. Sometimes selection bias is used to refer only to 
differential inclusion of clusters by intervention conditions. More specifically, “identification bias” refers to biases 
which are induced by differential application of the inclusion / exclusion criteria [Higgins 2016]. The term 
"recruitment bias" refers to biases which are induced by differential recruitment into the trial by the health care 
practitioner or to biases induced by individuals differentially declining to participate.  
Item 10a: Inclusion of clusters 
Standard CONSORT item: Not included in original CONSORT statement. 
CONSORT cluster extension: Who generated the random allocation sequence, who enrolled clusters, and who 
assigned clusters to interventions. 
Extension for SW-CRTs: Who generated the randomisation schedule, who enrolled clusters, and who assigned 
clusters to sequences.  
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Example: “We will recruit a convenience sample of practices from within our network of family physician office 
contacts within the London, Ontario and Stratford, Ontario communities. A collaborating family physician will 
send an introductory email to potential family physician contacts, inviting them and their practice to consider 
participating. We will then arrange an in-person meeting with family physicians from interested sites to introduce 
our study and obtain written agreement from family physicians and offices agreeing to participate that meet our 
eligibility criteria. A statistician blinded to cluster identity and not involved in the intervention delivery will 
generate the allocation sequence using computer-generated random numbers.” [RegisterNow-1 Trial] 
 
Explanation: Knowledge of who implemented the randomisation procedures at the level of the cluster is required for 
ascertaining if selection biases are possible.  
It is important to have a separation of roles between those who generate the randomisation schedule and those 
who recruit, enrol and assign clusters to the sequence (as in the Example). If the person who generated the 
randomisation was also responsible for recruiting the clusters, this could mean that there was an increased risk of 
selection bias. This is best achieved by having a person independent of the trial doing the randomisation. This will be 
less important in trials where the randomisation takes place after recruitment of all clusters.  
Item 10b: Inclusion of participants 
Standard CONSORT item: Not included in original CONSORT statement. 
CONSORT cluster extension: Mechanism by which individual participants were included in clusters for the 
purposes of the trial (such as complete enumeration, random sampling). 
Extension for SW-CRTs: Mechanism by which individual participants were included in clusters for the purposes of 
the trial (such as complete enumeration or random sampling; continuous recruitment or ascertainment, or 
recruitment at a fixed point in time), including who recruited or identified participants. 
 
Example 1 (Complete enumeration with continuous ascertainment): “The study included all patients admitted to 
16 acute adult wards of one general hospital over a 32-week period.” [Critical Care Outreach Trial] 
 
Example 2 (Random sampling): “Data collection for the evaluation study will focus on adults aged 18 years and 
over. The study will use a repeated cross-sectional design, in which a random sample of people within each 
cluster will be surveyed at each stage. A complete list of all households in each of the 128 study villages will be 
obtained using the Postcode... The order in which households are approached to participate in the survey at each 
stage will be randomly generated...One adult per household will be randomly selected.” [DAVE Trial Protocol] 
 
Example 3 (Continuous recruitment): “Then, the leaders of the nursing homes are responsible for the recruitment 
of the units and the residents according to the inclusion and exclusion criteria of the study. Here, all eligible 
participants of the participating units are invited to participate. Before the recruitment procedure will commence, 
each leader of the nursing homes will attend a kick-off meeting held by a senior investigator about the inclusion 
and exclusion criteria and the planned recruitment strategy. For the participants who drop out of the trial, we are 
planning to monitor the reasons (for example, death or moving) and perform a sensitivity analysis at the end of 
the trial to determine whether they differ according to certain characteristics (for example, the prevalence of the 
challenging behavior or gender). Residents who are newly admitted to clusters during follow up will also be 
included in the study …” [FallDem Trial] 
 
Explanation: Individual participants can be included in a SW-CRT in many different ways. Sometimes, participants are 
not recruited into a trial, but rather their data are used from routinely collected sources (Example 1). In this case it is 
common to take a complete enumeration of the cluster or at least those meeting the eligibility criteria. Alternatively, 
a sample of individuals from the cluster might be asked to complete data assessments or questionnaires in each 
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period (Example 2). Alternatively, participants might be recruited to participate in the trial. This recruitment might 
take place continuously (Example 3) or at a fixed point in time before the start of the trial.  
Knowledge of how participants are included in the trial can help assess the likelihood of identification and 
recruitment bias. Trials with complete enumeration are less likely to suffer from these biases (Example 2). Where 
participants are identified or recruited after randomisation (as in Examples 1 and 3), either a complete enumeration 
of the cluster or recruitment/identification by someone who is blind to allocation can help mitigate recruitment and 
identification biases. Therefore, clear reporting of who recruited or identified participants and whether or not such 
individuals were blind to allocation is important so readers can determine the risks for bias. Identification and 
recruitment biases will not occur in designs in which participants are recruited prior to randomisation.  
Item 10c: Consent 
Standard CONSORT item: Not included in original CONSORT statement. 
CONSORT cluster extension: From whom consent was sought (representatives of the cluster, or individual cluster 
members, or both), and whether consent was sought before or after randomisation. 
Extension for SW-CRTs: Whether, from whom and when consent was sought and for what; whether this differed 
between treatment conditions.  
 
Example 1 (Individual-level consent): “Written informed assent was obtained from all participating children as 
well as parental consent. Only children who provided both assent and parental consent were eligible to take 
part.” [SBP Trial] 
Example 2 (Cluster and individual-level consent): “Criteria for inclusion are informed consent obtained from 
people with dementia or their legal representative.…All of the nursing staff working in one of the two 
participating wards of the nursing home must provide their informed consent” [FallDem Trial] 
 
Explanation: Obtaining informed consent for participation, study interventions, and data collection procedures in 
clinical trials is an integral principle of research ethics and international human rights law [IEHR 2016; UN 1966]. The 
process by which consent was obtained can lead to biases [Campbell 2012]. It is important to describe what consent 
was for (e.g. exposure to the intervention or use of data), whether consent was sought before or after 
randomisation, and whether the type of consent differed between intervention and control conditions.  
In SW-CRTs there can be cluster-level research participants (e.g., health-care practitioners) and individual-level 
research participants (e.g. patients) [Taljaard 2013]. It is therefore important to identify explicitly from whom 
consent was obtained in the study (Example 2) or to state that consent was not obtained. Furthermore, in most 
cluster trials someone provides access to the cluster; such individuals are often called “gatekeepers” or “cluster 
guardians” [Edwards 1999]. Gatekeeper permission for trial participation is different to consent from cluster-level 
research participants, such as health providers, for their own participation in the study. 
In cluster randomised trials in which the treatment is delivered at the level of the cluster, it may not be possible to 
obtain consent for exposure to the intervention or control condition as the intervention may be impossible to avoid 
(as would be the case in Example 1 under Item 10b); however, consent can still be taken for use of data (implied by 
return of questionnaire data in Example 2 under Item 10b). It is therefore important to clearly report what consent 
was for. If participants recruited to the control and intervention conditions are given different information when 
their consent is taken, this can lead to bias [Eldridge 2005]. The information provided about the objectives of the 
study can itself prompt participants to act differently. For example, participants enrolled in a study of an intervention 
to increase uptake of HIV screening, who are fully informed about the objectives of the study, might increase uptake 
of screening irrespective of allocation to the intervention condition. This is known as the Hawthorne effect 
[McCarney 2007]. Reporting what information was provided to participants can allow readers to judge the risks of 
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such biases. A recent systematic review found that of the small number of SW-CRTs that reported whether or not 
consent was obtained, only a small proportion reported explicitly what this consent was for, and none reported 
when the consent was taken [Taljaard 2017].  
Sometimes a research ethics committee might deem it appropriate that the study proceed without the informed 
consent of research participants (i.e. a waiver of consent) or the research ethics committee may otherwise modify 
informed consent requirements (i.e. modification of consent). When a waiver or modification of consent has been 
granted by a research ethics committee, it should be reported and a justification given. It should be clear whose 
consent was waived and whether the waiver pertains to study participation, data collection, or both. Not all 
jurisdictions allow for a waiver or modification of consent. Information on data collection procedures in the trial, 
e.g., whether data are anonymous or pseudo-anonymous, and whether they were routinely collected, can provide 
clarity around ethical aspects of the trial. When appropriate it can be useful to include any participant consent forms 
in appendices, which will allow readers to infer precisely the information provided to participants.  
Methods: Blinding 
Item 11a: Blinding 
Standard CONSORT item: If done, who was blinded after assignment to interventions (for example, participants, 
care providers, those assessing outcomes) and how. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: If done, who was blinded after assignment to sequences (for example, cluster level 
participants, individual level participants, those assessing outcomes) and how. 
 
Example 1 (Blinding not possible): “Blinding to the intervention (i.e., the type of water being received) is not 
possible due to potential differences in turbidity of untreated and RBF (Riverbank Filtration)-treated river water.” 
[Riverbank Filtration Trial] 
 
Example 2 (Blinding partially possible): “Residents did not know when the intervention was being implemented or 
what the programme elements were. Interviewers who administered the outcome questionnaires were masked 
to intervention implementation or depression treatment, and to previous test results. Data analysts were masked 
to whether a specific resident had been exposed to the intervention and to when the intervention was 
implemented in a unit, but were not masked during post-hoc analyses.” [Depression Management Trial] 
 
Explanation: SW-CRTs are often used to evaluate interventions for which it is impossible to blind participants or 
clusters to whether they are in the intervention or control condition, but nonetheless it is important to report clearly 
whether or not blinding was used and if so, who exactly was blinded to aspects of the trial (Example 1).  
Often outcomes are collected at multiple levels (e.g. hospitals (e.g. team climate outcomes), clinicians (e.g. 
knowledge, skills, practice outcomes), patients (e.g. pain)). The possibility of blinding may be different depending on 
the level of participants (e.g. clinicians or patients) and may depend on the type of consent required (Item 10c). The 
degree of blinding should be reported at each level of the trial (e.g. clusters, participants as in Example 2) and 
whether the blinding differed in control and intervention conditions. Researchers should also specifically report 
blinding with respect to all outcomes. Blinding of those assessing outcomes should be clearly reported.  
A systematic review has found that most SW-CRTs do not report clearly who was blinded and what people were 
blinded to [Taljaard 2017]. Whether or not and who was blinded, and when, is best reported by the use of a timeline 
diagram [Caille 2016].  
Item 11b: Blinding 
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Standard CONSORT item: If relevant, description of the similarity of interventions. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: If relevant, description of the similarity of treatments. 
 
Explanation: In trials with a placebo it is important to provide evidence of the similarity of the control condition to 
the intervention condition (i.e. to provide evidence of the blinding). However, In SW-CRTs it would be unusual to 
have a placebo and often participants are not blind to their allocation status. Sometimes, a minimal level of 
intervention is provided in the control condition in an attempt to keep participants blinded to their status as 
intervention or control participants. When appropriate such minimal level interventions should be described in full. 
Methods: Statistical methods 
Item 12a: Statistical methods 
Standard CONSORT item: Statistical methods used to compare groups for primary and secondary outcomes. 
CONSORT cluster extension: How clustering was taken into account. 
Extension for SW-CRTs: Statistical methods used to compare treatment conditions for primary and secondary 
outcomes including how time effects, clustering and repeated measures were taken into account.  
 
Example 1 (Allowance for clustering and secular trends): “A generalised linear mixed model was used for 
categorical outcomes, and a linear mixed model was used for continuous outcomes, adjusting for age, gender, 
ethnicity and school terms (i.e., secular trend). The cluster effect by school and correlation between repeated 
measurements on the same child over time were taken into account in the multilevel analysis.” [SBP Trial] 
 
Example 2 (Cluster level analysis): The primary outcome (diarrhoeal prevalence) will be calculated for each cell in 
the stepped wedge design by aggregating over all individuals surveyed in each village during each time period. 
Estimation of intervention effects will be obtained from a linear regression of the logarithm of the village-
aggregated prevalence adjusting for seasonal effects and incorporating village as a fixed effect. The intervention 
effect coefficient will be exponentiated to produce an estimated relative reduction (with 95% CIs) in the overall 
prevalence of diarrhoea in the intervention periods (post-RBF) compared with control periods (piped but 
unfiltered water). This analysis model controls for both clustering of individuals within villages and for repeated 
assessments of villages over time... We will use multiple-imputation to impute missing outcomes at the individual 
person level which will then be aggregated for the village-level analyses.” [Riverbank Filtration Trial] 
 
Example 3 (Intention-to-treat analysis): “For the “intention-to-treat” analysis an indicator of whether an 
observation occurred pre- or post-randomisation was included in the regression model. To allow for delays in 
implementation a separate “per protocol” analysis was performed with the observations now placed into one of 
the three categories: “pre-randomisation”, “post-randomisation but pre-implementation” and “post-
implementation…” [FIT Trial] 
 
Explanation: The statistical methodology should be clearly reported to allow replication. Where possible it can be 
helpful to provide a reference to the statistical methodology used. In a SW-CRT, clusters are randomised to 
sequentially initiate the intervention. Observations collected under the control condition are therefore, on average, 
from an earlier calendar time than observations collected under the intervention condition. Changes external to the 
trial may create underlying secular trends. Likewise participants, if repeatedly measured over the duration of the 
study, may get sicker or recover over time. This means that time is a potential confounder. Analysis of a SW-CRT 
should adjust for time effects [Hussey 2007] irrespective of their statistical significance; failure to do so risks biasing 
the estimate of the intervention effect, which could lead to declaring an intervention effective when it is ineffective 
or ineffective when it is effective [Hemming 2017]. It is therefore essential to report if and how time effects were 
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allowed for. If time is measured continuously, time can be modelled parametrically; if time is measured discreetly 
then time can be modelled categorically. Furthermore, SW-CRTs typically include only a small number of clusters 
[Martin 2016] and so pre-specification of important prognostic factors to use in a fully adjusted analysis (in 
mitigation of the likelihood of imbalance due to sampling variation) might also be undertaken [Senn 1994]. 
In a parallel CRT, randomisation at the level of the cluster needs to be allowed for at the analysis stage (unless 
cluster level data are being analysed). In a SW-CRT, as clusters (and possibly individuals) are repeatedly measured 
over time, there may be some reduction in the strength of correlation between measurements within the same 
cluster over time [Hooper 2016]. Failure to appropriately model the correlation structure can lead to incorrect 
estimation of the precision of treatment effects [Thompson 2017]. It is therefore important to clearly describe the 
correlation structure used in the analysis.  
The analysis should also describe how deviations from the randomisation schedule were accommodated (Example 
3). A more detailed consideration of this point is given under Item 16 (numbers analysed).  
Item 12b: Additional statistical methods 
Standard CONSORT item: Methods for additional analyses, such as subgroup analyses and adjusted analyses. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Methods for additional analyses, such as subgroup analyses and adjusted analyses. 
 
Example (Time varying effect of intervention): “Furthermore, a delayed intervention effect of the CCs (Case 
Conference i.e. intervention) is assumed because the nurses need time to implement the procedure. Thus, the 
duration of the intervention in months must be considered.” [FallDem Trial] 
 
Explanation: SW-CRTs, like other trial designs, will commonly investigate subgroup differences and may perform 
adjusted analyses. In trials with a small number of clusters, investigating sensitivity to model assumptions will be 
important [Taljaard 2016].  
Of some importance in a SW-CRT is time by treatment interactions. Treatment by time interactions are treatment 
effects which change as the study progresses (not to be confused with secular changes which represent changes in 
the outcome under the control condition– Table 2 Key concept 1). These changing treatment effects are important 
because observations contributing to the analysis will comprise a mixture of times since roll-out of the intervention. 
Interventions delivered at a single occasion (and not repeated to ensure it creates a permanent effect) might have 
an impact which changes with increasing time since roll-out (for example, the effect of the intervention might be 
quite large immediately after roll-out and then its impact might start to wane). If interventions are refined over time 
then their effect will also change over the duration of the study. Few trials if any have clearly investigated these time 
by treatment interactions [Davey 2015; Martin 2017], although many interventions have been assessed as being at 
risk of time by treatment interactions [Davey 2015]. The example above makes an acknowledgement of the 
possibility of a delayed effect, although gives limited detail as to how it will be investigated.  
Of particular interest in a SW-CRT might be whether the intervention has a delayed effect (perhaps because its 
anticipated effect is not expected to materialise immediately (i.e. a lag effect); or if the intervention effect varies by 
time since exposure (e.g. an effect that decays over time or an effect that improves over time), perhaps because the 
effect of the intervention might be expected to wane with increasing time since exposure, particularly so in 
educational type interventions [Hughes 2015]; or perhaps due to the intervention being refined over the course of 
the roll-out.  
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Also of interest might be whether the effect of the treatment varies between sequences, perhaps because 
participants get sicker (or recover) with longer duration in the control condition and the treatment is not anticipated 
to have the same effect in sicker participants [Copas 2015].  
Results: Participant flow  
Item 13a: Participant flow 
Standard CONSORT item: For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome. 
CONSORT cluster extension: For each group, the numbers of clusters that were randomly assigned, received 
intended treatment, and were analysed for the primary outcome. 
Extension for SW-CRTs: For each treatment condition or allocated sequence, the numbers of clusters and 
participants who were assessed for eligibility, were randomly assigned, received intended treatments and were 
analysed for the primary outcome (Figure 3).  
 
Item 13b: Participant attrition  
Standard CONSORT item: For each group, losses and exclusions after randomisation, together with reasons 
CONSORT cluster extension: For each group, losses and exclusions for both clusters and individual cluster 
members. 
Extension for SW-CRTs: For each treatment condition or allocated sequence, losses and exclusions for both 
clusters and participants with reasons. 
 
Example Flow chart by treatment condition and sequence (cross-sectional design): Supplementary Figure S2 
(Long-live Mothers Trial) 
 
Explanation: Information on the number of clusters and participants who were assessed for eligibility and outcomes 
along with the number of losses and exclusions (i.e. withdrawals) allows the reader to assess the risk of differential 
inclusion and attrition.  
Any flow chart should allow the reader to examine the nature of any differential inclusion and attrition by allocated 
sequence, treatment condition, and over time (see Example Figure S2). Because there are many different types of 
SW-CRTs there is unlikely to be one flow-chart that will be applicable for all SW-CRTs. How the flow chart is 
constructed will depend on how many sequences and clusters there are, whether participants contribute repeated 
measures, and whether participants can join and leave the study. This information could be presented by allocated 
sequence but might also be presented by treatment conditions.  
Including time periods in the flow chart is important to allow for assessment of differential participation over time. 
When different participants are sampled in each period, each participant will, in theory, be exposed to either the 
intervention or control condition. In this case, summarising the number of participants by treatment condition is 
possible. Where the same participant contributes multiple measurements, each participant may provide 
measurements under both intervention and control conditions. In this case, summarising the number of participants 
by allocated sequence, along with the average number of measurements contributed by each participant, is more 
appropriate.  
Reporting the number of clusters and participants approached, eligible and included along with the reasons for non-
participation is important to allow an assessment of study generalizability, and perhaps even more importantly, of 
biases due to differential participation between treatment conditions (or sequences). For example, in a parallel CRT 
without blinding of participants to treatment condition at the time of recruitment, a higher rate of consent among 
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those recruited to the intervention condition can indicate recruitment bias [Caille 2016]. Information on reasons as 
to why participants or clusters are not included allows a reader to assess the appropriateness of exclusions.  
Results: Recruitment  
Item 14a: Recruitment  
Standard CONSORT item: Dates defining the periods of recruitment and follow-up. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Dates defining the steps, initiation of intervention and deviations from planned dates. 
Dates defining recruitment and follow-up for participants. 
 
Example 1 (Step dates): “Twenty-two villages received the intervention in the second period (April-June 2011), 36 
in the third period (September-November 2011), 35 in the fourth period (April-June 2012), and 35 in the fifth 
period (September-November 2012).” [DAVE Trial] 
 
Example 2 (Deviations from planned dates): “There were 60 study wards in the 16 randomised hospitals, of which 
33 (22 ACE and 11 ITU) in 13 hospitals went on to implement the intervention, with a mean (SD) delay in 
implementation of 5 (4) months …and a mean (SD) duration of implementation of 12 (7) months. Eight wards 
began implementation very late, and for these the end of the trial was extended to December 31st 2009 to 
ensure that they had a year of data collection post-implementation.” [FIT Trial] 
 
Explanation: Dates defining periods of recruitment of participants can be reported where appropriate; in some 
designs these dates will be at the beginning of the study before any cross-over of clusters occurs; in other designs 
recruitment will be continuous throughout the study. In some studies there will be no direct participant recruitment, 
but identification of data from participants from routine data sources. 
Reporting of other key dates are also important in a SW-CRT. These dates include the dates defining when the study 
was undertaken and dates defining the steps. Dates defining the start and end of the roll-out phase, as well as the 
dates of the steps are useful to demonstrate if the trial was implemented as planned (Example 1). Dates should be 
presented so that they can be easily related to the planned timing of the steps as described in Item 3a. Reporting 
deviations from planned dates is particularly important in the SW-CRT as they demonstrate deviations from the 
randomised schedule (Example 2).  
Dates defining implementation of interventions will allow assessment of when the intervention is fully implemented 
in each cluster. Dates defining actual implementation of the intervention should be specified. The realised time for 
an intervention to become fully implemented may differ from that which was planned. This allows assessment of 
whether all observations collected under the intervention condition were fully exposed to the intervention; it also 
allows assessment of whether any observations collected under the control condition were likely contaminated by 
the intervention. Reporting dates also allows inferences about external influences which may have affected secular 
trends.  
Item 14b: Recruitment 
Standard CONSORT item: Why the trial ended or was stopped. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Why the trial ended or was stopped. 
 
Explanation: Readers are referred to the CONSORT statement and the extension to the CONSORT statement for 
examples and explanation [Schulz 2010, Campbell 2012].  
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Results: Baseline data 
Item 15: Baseline data 
Standard CONSORT: A table showing baseline demographic and clinical characteristics for each group. 
CONSORT cluster extension: Baseline characteristics for the individual and cluster levels as applicable for each 
group. 
Extension for SW-CRTs: Baseline characteristics for the individual and cluster levels as applicable for each 
treatment condition or allocated sequence.  
 
Example 1 Baseline table by treatment condition (cross-sectional design): Supplementary Table S2 (DAVE Trial) 
Example 2 Baseline table by allocated sequence (open cohort design): Supplementary Table S3 (Depression 
Management Trial) 
 
Explanation: In a parallel CRT a summary of the cluster and participant level characteristics at baseline by treatment 
condition can allow assessment of the success of randomisation and provides a description of the included sample. 
In trials with post-randomisation recruitment, this table can allow an assessment of potential biases.  
The term “baseline” in a SW-CRT can be confusing because of the longitudinal nature of the design. We use the term 
“baseline characteristic” to mean a characteristic which was either measured before exposure to the control or 
intervention condition, or which is not expected to be influenced by the treatment conditions (e.g. age). In designs in 
which observations are made on different participants in each period, these baseline characteristics will often 
pertain to measurements made  just prior to the switch from control to intervention condition (i.e. not at the start of 
the trial); whereas in designs where participants are repeatedly assessed, these characteristics might be measured 
prior to randomisation. Cluster level characteristics can often be measured prior to randomisation and are less likely 
to change over time.  
For SW-CRTs in which observations are made on different participants in each period, the summary of baseline 
characteristics could be presented by treatment condition or by allocated sequence. For example, the DAVE Trial, 
which measures different participants in each period, reports its baseline table by treatment condition (Table S2).  
For SW-CRTs in which the same participants are repeatedly assessed in each of the periods, the baseline 
characteristics of participants will normally be presented by allocated sequence rather than by treatment condition. 
This is because most participants will be observed first under the control and then intervention condition. The 
Depression Management Trial (Table S3) provides summary characteristics by allocated sequence.  
Results: Numbers analysed  
Item 16: Numbers analysed 
Standard CONSORT: For each group, number of participants (denominator) included in each analysis and whether 
the analysis was by original assigned groups. 
CONSORT cluster extension: For each group, number of clusters included in each analysis. 
Extension for SW-CRTs: The number of observations and clusters included in each analysis for each treatment 
condition and whether the analysis was according to the allocated schedule. 
 
Example 1 (Numbers by treatment condition): “A total of 5295 surgical procedures were carried out throughout 
the stepped wedge cluster RCT, that is, 2212 in control and 3083 (of which 2263 had the SSC performed) after 
implementation of the SSC (Surgical Safety Checklist). Patients (14.9%; 667/4475) underwent more than 1 
procedure. The control and SSC study steps included 1778 and 2033 unique patients, respectively.” [Surgical 
Checklist Trial] 
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Example 2 (Intention-to-treat vs. per protocol): “The flow diagram shows there were 60 study wards in the 16 
randomised hospitals, of which 33 (22 ACE and 11 ITU) in 13 hospitals went on to implement the intervention… 
For the primary outcome, intention-to-treat analysis was conducted for the 60 wards randomised into the 
intervention, and per-protocol analysis was performed for the 33 implementing wards…” [FIT Trial] 
 
Explanation: The number of observations by treatment condition should be reported for analyses of all outcomes 
(Example 1). For some outcomes this information will be included in a flow chart although not all flow charts for a 
SW-CRT will give an immediate summary of this information by treatment condition. When the same participants are 
repeatedly measured across the time periods, each participant will have been exposed to both treatment conditions 
and so this information can be reported either by giving the total number of observations (by treatment condition) 
or as the number of participants in the study and average number of assessments per participant under each 
treatment condition. Where different participants contribute to each measurement period, it might be useful to 
have information on the number of participants per cluster-period. Such information might be most easily reported 
in a diagram rather than in text (Figure 3).  
Sometimes clusters (and perhaps participants) will not receive the intervention condition as per the randomisation 
schedule (Example 2). In a parallel trial an intention-to-treat analysis performs the analysis according to the groups 
to which participants or clusters were originally assigned [Moher 2012]. In a SW-CRT this might be interpreted as 
analysis of clusters and participants treated as exposed to the intervention according to the dates of the 
randomisation schedule (i.e. according to the planned dates). The application of this principle would mean that 
clusters are treated as exposed to the intervention if the observation comes from a time period post allocated cross-
over date. When a SW-CRT has randomised clusters to actual dates of transitioning from control to intervention, an 
intention-to-treat analysis following this interpretation is logical.  
Alternatively, a SW-CRT might be considered as randomising the order that the clusters transition from control to 
intervention (although when there are multiple clusters per sequence, several clusters share the same rank-order). 
In this situation an intention-to-treat analysis might be interpreted as analysis of clusters and participants treated as 
exposed to the intervention according to the order of the randomisation schedule (i.e. according to the planned 
order of roll-out). The application of this principle would mean that clusters are treated as exposed to the 
intervention only after the intervention has been implemented in that cluster, provided the order of the allocation 
did not deviate from that planned.   
Providing information on the number of clusters (and participants) contributing to all analyses allows assessment of 
whether the analysis has been conducted with respect to the randomised cross-over schedule – which might not be 
in strict accordance with any pre-specified dates; or to the actual cross-over dates that may deviate from planned 
dates due to delays in implementation.  
Sometimes a cluster may drop out from some purposively collected outcome assessments, but still contribute data 
from routinely collected sources for other outcome variables. If the numbers included in secondary analyses differ 
from those included in primary analyses, information on differential attrition (or participation) across clusters or 
periods can be provided in the text (similar to information depicted in the flow chart for the primary outcome 
(Figure 3). 
Results: Outcomes and estimation  
Item 17a: Outcomes and estimation 
Standard CONSORT item: For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision (such as 95% confidence interval). 
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CONSORT cluster extension: Results at the individual or cluster level as applicable and a coefficient of intra-cluster 
correlation (ICC or k) for each primary outcome. 
Extension for SW-CRTs: For each primary and secondary outcome, results for each treatment condition, and the 
estimated effect size and its precision (such as 95% confidence interval); any correlations and time effects 
estimated in the analysis.   
 
Example 1 (Time adjusted treatment effect): “A total of 321 (10.8%) unexposed patients were started on either 
antihypertensives or statins, and 577 (19.7%) exposed patients. The time-adjusted mean difference in proportion 
of patients initiating either treatment was 15.5% (95% CI = 3.9 to 27.1).” [Targeted Case Finding Trial] 
 
Example 2 (Secular trend): Supplementary Figure S3 [FIT Trial] 
 
Example 3 (Correlations): “The ICC in the time-adjusted analysis for initiation of either treatment was 0.014 (95% 
CI = 0.005 to 0.038).” [Targeted Case Finding Trial] 
 
Explanation: A summary of the findings for each primary and secondary outcome should be provided for each 
treatment condition. This will allow a description of the severity or prevalence of the outcome in the sample 
(Example 1). In addition, reporting of results by treatment condition allows estimation of an unadjusted effect of the 
intervention for comparison with a time adjusted effect (as in Example 1).  
Treatment effects should be reported along with 95% Confidence Intervals (CI). A SW-CRT which does not adjust for 
time is analogous to a simple uncontrolled before-and-after experiment; therefore, it should be clearly reported if 
the primary and secondary outcomes were adjusted for time (Example 1). To allow an understanding of the potential 
impact of secular trends it can be helpful to describe the secular trend – either in a figure or as regression 
coefficients. Ideally this should be done by calendar time and should represent the trend in the clusters yet to be 
exposed to the intervention (Example 2: Figure S3). In some SW-CRTs participants will be recruited at the very 
beginning of the trial and measured repeatedly. In chronic conditions these participants may naturally regress over 
the duration of the study; in acute conditions they may recover. Whilst not a secular trend per se, such effects still 
may lead to confounding of the intervention effect with time and so time should be adjusted for.  
Reporting any estimated coefficients of intra-cluster correlation (ICCs) can be informative for the planning of future 
trials (Example 3). Correlation structures are more complex than in a parallel cluster trials conducted at a single 
cross-section in time; therefore, analysis (and reporting) of a single measure of correlation such as the ICC might not 
be sufficient [Kasza 2017]. Relevant correlation coefficients might include correlations between observations in the 
same cluster and same time period (within-period ICC); correlations between observations in the same cluster but 
different time periods (between-period ICC), as well as between-period and within-period correlations on the same 
individual [Hooper 2016]. It is important to be explicit about the types of correlations being reported [Martin 2016b]. 
Reporting of variance components is an alternative to intra-cluster correlations, particularly for non-continuous 
outcomes [Hayes 1999]. When intra-cluster correlations are reported for binary outcomes, clearly indicating the 
scale (e.g. proportions or logistic scale) can help interpretation [Eldridge 2009].  
Item 17b: Binary outcomes 
Standard CONSORT item: For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended. 
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Explanation: In addition to reporting a relative measure of the effect of the intervention it can be helpful to report an 
absolute measure of the effect: while absolute measures of effects are more easily understood, relative measures of 
effects are often more stable across different populations [Ukoumunne 2008]. 
While reporting relative and absolute measures of effects is recommended, further methodological work is required 
to determine optimal methods of analysis that yield such estimates. Current approaches include fitting two separate 
models (for example a binomial model with log link to report the relative risks; and a binomial model with an identity 
link to report a risk difference) or by fitting one model and using a transformation to report the other measure of 
treatment effect [Pedroza 2016].  
Model based methods for achieving estimates on both scales have been investigated in parallel CRTs in which the 
model is unadjusted for confounders [Ukoumunne 2008]; and others have evaluated the performance of these 
models when covariate adjustment is required [Pedroza 2016].  
Results: Ancillary analyses   
Item 18: Ancillary analyses   
Standard CONSORT item: Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory. 
 
Explanation: There are several analyses that can be considered to examine deviation from model assumptions, for 
example, variations in secular trends across groups of clusters [Hemming 2017]; interactions of the intervention 
effect with sequence; and whether the effect of the intervention might change with increasing duration of exposure 
(Item 12b). In the reporting of these ancillary analyses, any limitations due to the assumptions made should be 
noted.  
Results: Harms  
Item 19: Harms 
Standard CONSORT item: All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms). 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Important harms or unintended effects in each treatment condition (for specific guidance 
see CONSORT for harms). 
 
Explanation: Readers are referred to the CONSORT statement and the extension to the CONSORT statement for 
examples and explanation [Schulz 2010; Campbell 2012].  
Discussion  
Item 20: Limitations 
Standard CONSORT item: Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses. 
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Explanation: Estimated intervention effects from a SW-CRT will almost always be model-based estimates adjusting 
for time. There is a host of different models which can be used, but all make some assumptions. The assumptions 
made and potential limitations should be reflected on.  
Item 21: Discussion 
Standard CONSORT item: Generalisability (external validity, applicability) of the trial findings. 
CONSORT cluster extension: Generalisability to clusters and/or individual participants (as relevant) 
Extension for SW-CRTs: Generalisability (external validity, applicability) of the trial findings. Generalisability to 
clusters and/or individual participants (as relevant).  
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010, Campbell 2012].  
 
Item 22: Interpretation 
Standard CONSORT item: Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence. 
CONSORT cluster extension: No modification suggested 
Extension for SW-CRTs: Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Other information  
Item 23: Trial registration 
Standard CONSORT item: Registration number and name of trial registry. 
CONSORT cluster extension: No modification suggested.  
Extension for SW-CRTs: Registration number and name of trial r gistry. 
 
Explanation: The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial “as any research 
project that prospectively assigns people or a group of people to an intervention, with or without concurrent 
comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and 
a health outcome” [ICMJE]. The ICMJE states that all medical journal editors should require clinical trials to be 
registered (prior to the first patient enrolment) as a condition of publication. SW-CRTs of health related 
interventions meet the ICMJE’s definition of a clinical trial and so should wherever possible be registered as a clinical 
trial prior to the study start date.  
Reporting the name of the trial registry and the unique trial registration number facilitates crosschecking with the 
associated registry entry and allows assessment of whether there are any important changes to the trial design, and 
the potential for any bias (such as outcome reporting bias). Further, reporting details of the trial registration 
facilitates linking of multiple publications from the same trial, which is of particular importance for systematic 
reviews. If the trial has not been registered, this should be stated along with the reason. 
Studies examining trial registration rates have found that a large percentage of trials are not registered (e.g. 28% - 
44% [Azar 2015; Killeen 2014; Wetering 2012]). Further, in the trials that are registered, not all report the 
registration details in the trial publication, and not all are prospectively registered. A recent review that examined 
registration of SW-CRTS found that only 50% of SW-CRTs were prospectively registered [Taljaard 2017].   
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Item 24: Trial protocol 
Standard CONSORT item: Where the full trial protocol can be accessed, if available. 
CONSORT cluster extension: No modification suggested 
Extension for SW-CRTs: Where the full trial protocol can be accessed, if available. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Item 25: Funding 
Standard CONSORT item: Sources of funding and other support (such as supply of drugs), role of funders. 
CONSORT cluster extension: No modification suggested. 
Extension for SW-CRTs: Sources of funding and other support (such as supply of drugs), role of funders. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010, Campbell 2012].  
 
Item 26: Research Ethics Review 
Standard CONSORT item: Not included.  
CONSORT cluster extension: Not included  
Extension for SW-CRTs: Whether the study was approved by a research ethics committee, with identification of 
the review committee(s). Justification for any waiver or modification of informed consent requirements.  
 
Example 1 (Full review): “The study received ethical approval from the Sport and Health Sciences Ethics 
Committee at the University of Exeter (February 2011).” [DAVE Trial Protocol] 
Example 2 (Waiver of consent): “This study was reviewed by the Regional Committee for Medical and Health 
Research Ethics (Ref: 2009/561), which advised that use of routinely collected anonymized patient data is clinical 
service improvement and thus no further approval or patient consent is required.”[Surgical Checklist Trial] 
 
Explanation: The original CONSORT statement did not include an item on research ethics approval because it is an 
existing International Committee of Medical Journal Editors requirement that research “involving human data” 
should indicate whether the research was reviewed by a research ethics committee [ICMJE]. However, a systematic 
review found that only 75% of SW-CRTs reported review by a research ethics committee, possibly due to the 
classification of such studies, by some researchers, as service development or quality improvement. To encourage 
clear reporting about research ethics review of SW-CRTs we have therefore included this as a new item. This is 
consistent with the recent extension to the CONSORT statement for pilot studies, which also included this as a new 
item [Eldridge 2016]. An application number or reference number of the ethical approval should also be reported. If 
a study is deemed exempt from review by a research ethics committee, this should be reported together with a clear 
justification for the exemption from review.  
Conclusions  
The SW-CRT offers an exciting new opportunity to rigorously examine the effects of implementation, policy and 
service delivery interventions. The design is appealing in many respects, but also provides many challenges. It has 
noteworthy risks for biases including bias due to temporal trends and within-cluster contamination, as well as 
methodological complexities such as changes in correlation structures over time. Furthermore, perhaps because the 
design is being used in situations where researchers are not familiar with standards for reporting or conduct, SW-
CRTs have been noted to be particularly prone to inadequacies of ethical reporting, including research ethics review 
and (in common with many cluster trials) identification of research participants. This extension of the CONSORT 
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statement for SW-CRTs encourages researchers to reflect on the unique aspects of the SW-CRT and improve the 
clarity of reporting.  
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Table 1 Glossary of terms 
 
Term  Explanation  
Cluster The unit of randomisation.  
Cluster-period 
A grouping of observations by time of measurement and 
cluster. 
Step 
A planned point at which a cluster or group of clusters crosses 
from control to intervention.  
Period A grouping of observations by time of measurement.  
Duration of period Time (e.g. months) between each step.  
Sequence of treatments (often 
abbreviated to sequence or 
allocated sequence)* 
A sequence of codes defining the order of implementation of 
the treatment conditions for each cluster. More than one 
cluster can be allocated to each sequence. 
Intervention condition* The treatment under evaluation.  
Control condition  The comparator treatment. 
Transition period 
The time needed to fully embed the intervention. A transition 
period may have the same or different duration than a 
measurement period. 
Participant 
A participant is someone on whom investigators seek to 
measure the outcome of interest.  
Research participant 
A research participant denotes a human research subject from 
the standpoint of ethical considerations.  
Open cohort  
A study design in which participants are repeatedly assessed 
over a series of measurement points and can join and leave the 
study throughout its duration.  
Closed cohort  
A study design in which participants are repeatedly assessed 
over a series of measurement points and cannot join the study 
once it has started. 
Cross-sectional  
A study design in which different participants are measured at 
each measurement occasion.  
Complex intervention  An intervention that has multiple and interacting parts.  
Purposively collected data 
Data that are collected for the specific purpose of contributing 
to the trial (data that are not routinely collected). 
*Note the CONSORT statement uses the term “group” to refer to the allocated treatment, but for SW-CRTs we 
distinguish between the concepts of the allocated sequence and the treatment condition in any given period 
of that sequence, and avoid terminology such as “group” or “arm”. We use the term “treatment” in a generic 
way to refer to either the active treatment or comparator; and retain the use of the phrase “intervention 
condition” to refer to the active treatment of the trial; and the “control condition” to refer to the comparator.  
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Key concept Detailed Description Why this is important Mitigating strategies 
Imbalance of the 
design with respect 
to time 
In a SW-CRT, clusters are randomised to different sequences 
which dictate the order they initiate the intervention. 
Observations collected under the control condition are, on 
average, from an earlier calendar time than observations 
collected under the intervention condition.  
Changes external to the trial may create underlying secular 
trends. In addition, where the same participants are repeatedly 
assessed, their health status might improve (or worsen) over the 
study. Because time is associated with both the treatment 
condition and the outcome, it means that time is a potential 
confounder.  
Analysis and sample size should allow for 
the confounding effect of time. 
Repeated measures 
on same clusters and 
possibly same 
participants 
SW-CRTs make a series of measurements over time within 
each cluster. These repeated measurements can be on the 
same participants, different participants, or a mixture of the 
same and different participants at each measurement. 
Correlation structures are more complex than in a parallel cluster 
trial conducted at a single cross-section in time.  
Analysis (and consequently sample size 
calculations) should allow for the fact that 
data are not independent and 
dependencies might vary overtime. 
Within cluster 
contamination 
In SW-CRTs, some or all of the clusters will be exposed to 
both the control and intervention conditions. Participants can 
either have a relatively short exposure to the intervention 
(surgical intervention) or long exposure (change in care home 
policy).  
Where duration of exposure is short it is unlikely that individuals 
will be exposed to both the control and intervention condition. 
Where the duration of exposure is long, it may be possible that 
some participants are exposed to both the control condition the 
intervention condition.  
In trials with long exposure, delayed 
assessment of outcomes should be 
avoided to prevent participants recruited 
under the control condition later 
becoming exposed to the intervention 
condition.  
Delayed treatment 
effects and transition 
periods 
Sometimes the effect of the intervention is expected to 
materialise immediately, and sometimes there is a delay 
before its effect will be realised. 
 
When there is a delay before the effect of the intervention is 
realised the estimate of effectiveness can be attenuated.  
Where there is an expected delay before 
the effect of the intervention is 
materialised a transition period can be 
built into the design of the study.  
Time by treatment 
effect interactions 
SW-CRTs can evaluate interventions of many different forms. 
The intervention can be a one-off delivery involving a 
"permanent" change to a health care system, or it can be an 
intervention which may need to be repeated multiple times 
to ensure its effects are realised such as education of health 
professionals. Sometimes the intervention may be refined 
over the duration of the study.  
Interventions delivered at a single occasion (and not repeated to 
ensure it creates a permanent effect) might have an impact 
which changes with increasing time since roll-out (for example, 
the effect of the intervention might be quite large immediately 
after roll-out and then its impact might start to wane). If 
interventions are refined over time then their effect will also 
change over the duration of the study.  
If interventions are either refined over 
time or are not expected to create a 
permanent effect, an analysis examining 
how the effect of the treatment changes 
with time should be considered.  
Sampling of 
observations 
SW-CRTs can take a complete enumeration of the cluster, a 
random sample of individuals, or recruit participants into the 
trial. Furthermore, participants might be continuously 
recruited into the trial as they present; or all participants 
might be recruited at the beginning of the trial.  
Information on how observations were sampled is important to 
elicit risks of bias. Studies which take a complete enumeration 
have lower risks of bias as do studies which recruit all 
participants at a fixed point in time before randomisation has 
occurred; studies which continuously recruit participants have 
higher potential for identification and recruitment biases.  
Methods to reduce the risk of bias include 
taking a complete enumeration of the 
entire cluster-period, recruiting all 
participants before randomisation, or 
recruiting by someone independent to the 
study.  
Continuous or 
discrete time 
measurements  
Observations may be accrued continuously in time (e.g., as 
patients present to an emergency department and provide 
measurements after a follow-up period); or in discrete time 
(e.g., a survey questionnaire may be implemented at several 
discrete points in time).  
Where observations are accrued in continuous time, outcomes 
are more likely to be measured in continuous time; where 
outcomes are accrued in discrete time, outcomes are more likely 
to be measured in discrete time.  
Collecting exact timings of outcomes will 
ensure the full possible range of analysis 
methods can be implemented.  
Justification of study 
type 
Justifying the need for a staggered roll-out of the intervention 
using a SW-CRT, as opposed to a simple parallel arm 
implementation, is important because the SW-CRT is more 
Risks of bias in the SW-CRT may be higher than in a parallel CRT. 
For example, secular trends may be of concern in a SW-CRT, but 
not in a parallel design.  
SW-CRTs should be classified as research 
and so should be registered as a trial and 
should be submitted for review to an 
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complicated in its design, analysis, and implementation than 
the parallel CRT. It might also involve exposing a greater 
number of clusters or participants to the intervention. 
approved research ethics committee.   
Table 2 Key methodological considerations to consider in the reporting of a SW-CRT 
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Table 3 Checklist of information to include when reporting a stepped-wedge cluster randomised 
trial 
 
Section/Topic Item No Checklist item Page Number 
Title and abstract 
 1a Identification as a stepped-wedge cluster 
randomised trial in the title. 
 
1b Structured summary of trial design, methods, 
results, and conclusions (see separate SW-CRT 
checklist for abstracts). 
 
 
Introduction 
Background and 
objectives 
2a Scientific background. Rationale for using a cluster 
design and rationale for using a stepped-wedge 
design. 
 
2b Specific objectives or hypotheses.  
Methods 
Trial design 3a Description and diagram of trial design including 
definition of cluster, number of sequences, 
number of clusters randomised to each sequence, 
number of periods, duration of time between each 
step and whether the participants assessed in 
different periods are the same people, different 
people, or a mixture.  
 
3b Important changes to methods after trial 
commencement (such as eligibility criteria), with 
reasons. 
 
Participants 4a Eligibility criteria for clusters and participants.   
4b Settings and locations where the data were 
collected. 
 
Interventions 5 The intervention and control conditions with 
sufficient details to allow replication, including 
whether the intervention was maintained or 
repeated, and whether it was delivered at the 
level of the cluster, the individual, or both. 
 
 
Outcomes 6a Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed.  
 
6b Any changes to trial outcomes after the trial 
commenced, with reasons 
 
Sample size 7a How sample size was determined. Method of 
calculation and relevant parameters with 
sufficient detail so the calculation can be 
replicated (see separate checklist for SW-CRT 
sample size items). Assumptions made about 
correlations between outcomes of participants 
from the same cluster. 
 
7b When applicable, explanation of any interim 
analyses and stopping guidelines 
 
Randomisation: 
Sequence 
generation 
8a Method used to generate the random allocation 
to the sequences of treatments.  
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Table 3 Checklist of information to include when reporting a stepped-wedge cluster randomised 
trial 
 
8b Type of randomisation; details of any constrained 
randomisation or stratification if used. 
 
Allocation 
concealment 
mechanism 
9 Specification that allocation was based on 
clusters; description of any methods used to 
conceal the allocation from the clusters until after 
recruitment.  
 
 
Implementation 
 
10a Who generated the randomisation schedule, who 
enrolled clusters, and who assigned clusters to 
sequences.  
 
 10b Mechanism by which individual participants were 
included in clusters for the purposes of the trial 
(such as complete enumeration, random 
sampling; continuous recruitment/ascertainment, 
or recruitment at a fixed point in time), including 
who recruited or identified participants. 
 
 10c Whether, from whom and when consent was 
sought and for what; whether this differed 
between treatment conditions.  
 
Blinding 11a If done, who was blinded after assignment to 
sequences (for example, cluster level participants, 
individual level participants, those assessing 
outcomes) and how. 
 
11b If relevant, description of the similarity of 
treatments. 
 
Statistical 
methods 
12a Statistical methods used to compare treatment 
conditions for primary and secondary outcomes 
including how time effects, clustering and 
repeated measures were taken into account.  
 
12b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses. 
 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each treatment condition or allocated 
sequence the numbers of clusters and participants 
who were assessed for eligibility, were randomly 
assigned, received intended treatments and were 
analysed for the primary outcome.  
 
13b For each treatment condition or allocated 
sequence, losses and exclusions for both clusters 
and participants with reasons. 
 
Recruitment 14a Dates defining the steps, initiation of intervention 
and deviations from planned dates. Dates defining 
recruitment and follow-up for participants. 
 
14b Why the trial ended or was stopped  
Baseline data 15 Baseline characteristics for the individual and 
cluster levels as applicable for each treatment 
condition or allocated sequence. 
 
Numbers analysed 16 The number of observations and clusters included 
in each analysis for each treatment condition and 
whether the analysis was according to the 
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Table 3 Checklist of information to include when reporting a stepped-wedge cluster randomised 
trial 
 
 
allocated schedule. 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results 
for each treatment condition, and the estimated 
effect size and its precision (such as 95% 
confidence interval); any correlations and time 
effects estimated in the analysis.   
 
17b For binary outcomes, presentation of both 
absolute and relative effect sizes is recommended 
 
Ancillary analyses 18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory 
 
Harms 19 Important harms or unintended effects in each 
treatment condition (for specific guidance see 
CONSORT for harms) 
 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses. 
 
Generalisability 21 Generalisability (external validity, applicability) of 
the trial findings. Generalisability to clusters 
and/or individual participants (as relevant).  
 
Interpretation 22 Interpretation consistent with results, balancing 
benefits and harms, and considering other 
relevant evidence. 
 
Other information  
Registration 23 Registration number and name of trial registry.  
Protocol 24 Where the full trial protocol can be accessed, if 
available. 
 
Funding 25 Sources of funding and other support (such as 
supply of drugs), role of funders. 
 
Research Ethics 
review 
26 Whether the study was approved by a research 
ethics committee, with identification of the review 
committee(s). Justification for any waiver or 
modification of informed consent requirements.  
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Table 4 Noteworthy changes to the CONSORT 2010 statement and the 2012 extension for cluster trials 
 
 
 
 
 
 
 
 
 
 
 
 
Noteworthy changes to the CONSORT 
2010 Statement 
Separate presentation of the CONSORT checklist items for SW-CRTs (see Table 3).  
Modification of Item 2a (Background) to include rationale for use of a stepped-wedge 
design 
Extension of Item 3a (Design) to include a schematic representation of the design; and 
clarity over key design aspects (such as number of steps, number of observations per 
cluster-period).  
Extension of Item 7a and 12a (Sample Size and Statistical Methods) to include 
reference to the methods used to allow for adjustment for time and assumptions 
made about correlations.  
Extension of Item 12b (Auxiliary analyses) to include any sensitivity analyses for 
assumptions made about time effects. 
Extension of Item 13a (Participant flow) to include a modified flow-chart by allocated 
sequence (see Figure 3). 
Extension of Item 17a (Outcomes and Estimation) to report any adjustment for time 
effects; and presentation of secular trends (see Figure S2)  
Extended elaboration under Item 18 (Auxiliary analyses) to include reporting of any 
sensitivity analyses for any model based methods; and extended elaboration under 
Item 20 (Limitations) to include discussion of any limitations due assumptions made 
about time effects.  
Extended elaboration under Item 5 (Interventions) to include planned details on 
timings of interventions; and under Item 6 (Outcomes) timings of outcome 
assessments. This information, along with the corresponding realised dates under 
Item 14a (Recruitment Dates) allow determination of the risk of within cluster 
contamination.  
Addition of Item 26 (Research Ethics Review) to include reporting of ethical review 
and consent processes. 
 
 
Noteworthy deviations from the 
CONSORT 2012 extension for cluster 
randomised trials  
 
Modification of wording of Item 2b (Objectives) from “Whether objectives pertain to 
the cluster level, the individual participant level or both.” which was deemed 
ambiguous to “Specific objectives or hypotheses”. 
Modification of Item 9 (Allocation Concealment) to reference only allocation 
concealment from the unit of randomisation (i.e. cluster) and not participant (comes 
under Item 10b). 
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Table 6: Essential and additional information to report under sample size calculation (Item 7a) 
 
 Further explanation  
Essential information for reporting  
Level of significance State whether a one or two-sided test was used.  
Power  
Target difference  
Variation of outcome  For continuous variables this will be a standard deviation; and for binary variables this will be the control proportion.  
  
Number of clusters There should be clarity between the total number of clusters and the number of clusters allocated to each sequence. A 
diagram can be helpful. 
Number of sequences  
Average cluster size  There should be clarity between cluster size per measurement period and total cluster size. 
The assumed correlation 
structure  
The assumed intra-cluster correlation coefficient (ICC) and whether the ICC is time dependent or time independent. If time-
dependent, state the parameters that were assumed to accommodate the time-dependency, for example, the within-period 
ICC and the between-period ICC or the cluster autocorrelation coefficient, or any variance components.   
For binary outcomes it is important to report the scale of the correlations or variance components (e.g., proportions scale or 
logistic scale). 
Within person correlations Where the design includes repeated measurements on the same individual, describe the assumed correlation structure at 
the individual level, including if any decay in correlation in repeated measures on the same individual has been accounted 
for (e.g., an individual auto-correlation coefficient). 
 
  
Additional information for reporting 
Method used  Reference to the methodology used and statistical packages (including details of functions) used for implementation.  
Allowance for variation in cluster 
size  
Whether variation in cluster sizes were accommodated and how. This can include variation in total cluster sizes or variation 
in cluster-period sizes  
Allowance for attrition  This can include attrition both at the cluster level and the individual level.  If included, provide an explanation of how this 
was allowed for. 
Number of clusters per sequence If an unequal number of clusters per sequence was used, include information on whether this was accounted for in the 
sample size calculation.  
Allowance for transition periods State whether any transition periods were allowed for and how. This includes a description of the duration of the transition 
period and whether these data were excluded from the sample size calculation, or included with alternative coding of the 
intervention indicator 
Sensitivity analysis  This can include sensitivity to all parameters which might vary in the actual trial. A justification should be provided for all 
assumed sample size parameters 
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1 
 
Figure 1 Diagram of the standard stepped-wedge cluster randomised trial  
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Figure 2 Example of a diagram of a SW-CRT taken from the Riverbank Filtration Trial 
 
Taken from Figure 2 in McGuinness SL, O'Toole JE, Boving TB, Forbes AB, Sinclair M, Gautam SK, 
Leder  K. Protocol for a cluster randomised stepped wedge trial assessing the impact of  a 
community-level hygiene intervention and a water intervention using riverbank filtration technology 
on diarrhoeal prevalence in India. BMJ Open. 2017 Mar 17;7(3):e015036. doi: 10.1136/bmjopen-
2016-015036. PubMed PMID: 28314746; PubMed  Central PMCID: PMC5372111. 
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Assessed for 
eligibility 
(n=No. 
clusters) Excluded (n=No. of clusters): 
  Not meeting inclusion criteria (n=…) 
  Declined to participate (n=…) 
  Other reasons (n=…) 
Randomised (n=No. of clusters) 
Sequence 1 
n=No. of clusters allocated 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Period 1 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Period 2 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Period 3 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Period 4 
Sequence 2 
n=No. of clusters allocated 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Sequence 3 
n=No. of clusters allocated 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Assessed for eligibility (N=…) 
Received intervention (n=… , average cluster 
size, variance of cluster sizes) 
Did not receive intervention, give reasons (n=… 
clusters, average cluster size, variance of 
cluster sizes) 
Figure 3 Specimen flow chart for a SW-CRT by allocated sequence and period  
Shaded blue represents cluster under the control condition; white represents under the intervention condition. 
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Figure S1 Example of a diagram of a SW-CRT taken from the DAVE Trial Protocol 
 
Taken from Figure 1 in Solomon E, Rees T, Ukoumunne OC, Hillsdon M. The Devon Active Villages 
Evaluation (DAVE) trial: study protocol of a stepped wedge cluster randomised trial of a community-
level physical activity intervention in rural southwest England. BMC Public Health. 2012 Aug 
1;12:581. doi: 10.1186/1471-2458-12-581. PubMed PMID: 22849310; PubMed Central PMCID: 
PMC3496564. 
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Figure S3 Example of a secular trend taken from the FIT Trial  
 
 
Note: “Before randomisation” refers to observations under the control condition; and “after 
randomisation” to observations under the intervention condition.  
Taken from Figure 3 in Fuller C, Michie S, Savage J, McAteer J, Besser S, Charlett A, Hayward A, 
Cookson BD, Cooper BS, Duckworth G, Jeanes A, Roberts J, Teare L, Stone S. The Feedback 
Intervention Trial (FIT)--improving hand-hygiene compliance in UK healthcare workers: a stepped 
wedge cluster randomised controlled trial. PloS One. 2012;7(10):e41617. doi: 
10.1371/journal.pone.0041617. PubMed PMID: 23110040; PubMed Central PMCID: PMC3479093.  
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Table S1 Example of an abstract (results are made up) 
An integrated approach to improve care during delivery in a low income country: a stepped-wedge cluster 
randomized trial 
Background: Rural communities in low income countries, where most deliveries take place at home under the care of a 
traditional birth attendant, have high rates of complications. The objective of this study was to evaluate the impact of a 
package of interventions, with the aim of encouraging women to deliver at health centres and training traditional birth 
attendants, on adverse maternal and child health indicators.  
Methods: The intervention package was implemented in a random order using a stepped-wedge design across the six 
sub-districts of two purposively selected (high maternal morbidity) districts of the country over the period January-2014 
to January-2017. The intervention was implemented in sequentially with one of the six sub-districts transitioning to the 
intervention every four months. The randomisation was stratified by the two participating districts with one sub-district 
randomly selected to be allocated first in the order. Data on outcomes were collected on all births in all 33 health 
centres within the two districts from nine months before the first implementation until four months after the last 
implementation.  
The intervention encompassed three components. The first component consisted of the distribution of promotional 
materials encouraging health centre delivery. The second educational component sought to raise awareness among 
health centre personnel of the importance of the participation of traditional birth attendants and increase knowledge on 
the appropriate management of obstetric emergencies. The third training component focused on building capacity 
among health personnel. Main outcomes were number of health centre deliveries and maternal and perinatal morbidity; 
and perinatal mortality. Usual care continued over the control periods. Women, health care professionals and data 
collection were unblended to the intervention.  
Results: There were a total of 24,464 deliveries over the study period. Health centre deliveries per 100 live births 
showed an overall increase over the study period, although the adjusted (for secular trends and clustering) relative risk 
(aRR) was not statistically significant ((aRR 1.06, [CI: 0.94 - 1.32, p = 0.17]). . Furthermore, maternal morbidity decreased 
(aRR 0.78 [CI: 0.60 – 1.02, p = 0.07]), as well as perinatal morbidity (aRR 0.65 [CI: 0.55 - 1.15, p = 0.12]) and mortality 
(aRR 0.86 [CI: 0.65 - 1.29, p = 0.29]). 
Conclusions: This study found no statistically significant effect of an integrated approach to promote health centre 
delivery. The intervention holds some promise for decreasing maternal, perinatal morbidity and mortality.  
Trial registration: ClinicalTrials.gov, NCTXXXXX; ethical approval: National Institutional Review Board  
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Table S2 Example of a baseline table by control and intervention conditions taken from the DAVE 
Trial 
 
Taken from Table 1 in Solomon E, Rees T, Ukoumunne OC, Metcalf B, Hillsdon M. The Devon Active 
Villages Evaluation (DAVE) trial of a community-level physical activity intervention in rural south-
west England: a stepped wedge cluster randomised controlled trial. Int J Behav Nutr Phys Act. 2014 
Jul 18 
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Table S3 Example of a baseline table by allocated sequence taken from the Depression Management Trial  
 
Note that in this trial the authors have used the phrase “group” to refer to what we mean by “sequence of treatments”  
Taken from Table 1 in the Depression Management Trial: Leontjevas R, Gerritsen DL, Smalbrugge M, Teerenstra S, Vernooij-Dassen MJ, Koopmans RT. A 
structural multidisciplinary approach t depression management in nursing-home residents: a multicentre, stepped-wedge cluster-randomised trial. Lancet. 
2013 Jun 29;381(9885):2255-64. 
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3 
 
Summary 
This document presents the Consolidated Standards Of Reporting Trials (CONSORT) extension for the stepped-wedge 
cluster randomised trial (SW-CRT). The SW-CRT involves randomisation of clusters to different sequences that 
dictate the order (or timing) at which each cluster will switch to the intervention condition. The development of this 
statement was motivated by the unique design characteristics of this study e stepped wedge design, including the 
need to allow for time effects and because the design is increasingly being used. The guideline was developed using 
a Delphi survey and consensus meeting; and is informed by the CONSORT statements for individually and cluster 
randomised trials. Reporting items along with explanations and examples are provided. We include a glossary of 
terms, and explore the key properties of the SW-CRT which require special consideration in their reporting.  
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Introduction 
The CONSORT (Consolidated Standards Of Reporting Trials) statement, initially published in 1996 and updated in 
2001 and 2010, outlines essential items to be reported in a parallel arm individually randomised trial [Begg 1996; 
Rennie 2001; Schulz 2010]. The CONSORT extension for cluster randomised trials, initially published in 2004 and 
updated in 2012, extended this guidance for trials in which groups of individuals (clusters – for a full glossary of 
terms see Table 1) are randomised to different treatment conditions [Campbell 2004; Campbell 2012]. In recent 
years, a novel type of cluster randomized design - the stepped-wedge cluster randomised trial (SW-CRT) - has 
become increasingly popular [Brown 2006; Mdege 2011, Martin 2017]. The SW-CRT involves randomisation of 
clusters to different sequences. These sequences dictate the order (or timing) with which each cluster will switch to 
the intervention condition.  
The basic components of the design, as well as illustrative examples of studies which have used this design, have 
been described previously [Hemming 2015]. The unit of randomisation in these trials is the cluster with clusters (or 
groups of clusters) allocated to different sequences (as opposed to different “arms” in a parallel trial). These 
sequences dictate the number of time periods spent in the control condition and the number of time periods in the 
intervention condition. In Figure 1, for example, there are four clusters allocated to four different sequences. Each 
cluster contributes data to the analysis from each measurement period. In the example in Figure 1 there are five 
measurement periods. The point at which a cluster switches to the intervention condition is called a “step”. 
Sometimes a transition period is built into the design, during which the intervention is implemented in the cluster.  
This design has numerous methodological complexities, including potential confounding with time [Hemming 2017]; 
changes in correlation structures over time [Girling 2016; Hooper 2016; Kasza 2017]; the possibility of within cluster 
contamination over time [Copas 2015]; the possibility of time varying treatment effects [Davey 2015, Hemming 
2017]; and different design variations [Prost 2015; Hargreaves 2015], all of which increase the complexity of 
reporting [Hemming 2015]. Perhaps unsurprisingly, systematic reviews examining the adequacy of reporting of SW-
CRTs have revealed numerous inadequacies, including absence of essential details of the design, inconsistent use of 
terminology [Brown 2006; Mdege 2011; Martin 2016; Grayling 2017; Taljaard 2017]; frequent lack of clarity in 
reporting of adjustment for time effects [Hemming 2017; Martin 2017]; as well as frequent failure to report ethical 
review and trial registration [Taljaard 2017]. These findings suggest there is a need for a specific reporting guideline 
for this trial design. Here we report the results of a consensus process to develop an extension to the CONSORT 
statement for use with SW-CRTs. The ultimate goal of this extension is to improve the standards of reporting of this 
important and increasingly used research design. 
Scope of this statement 
This reporting statement should be followed when reporting results from any SW-CRT. In line with other CONSORT 
statements this guideline includes the minimum set of items that should be reported; it is not intended to be a 
comprehensive list of all possible items that could be reported. 
A wide variety of terminology has been used to describe aspects of the SW-CRT design. For the purpose of this 
reporting statement, the key components of the design are defined in Figure 1 and a glossary of terms is provided in 
Table 1.  with cin in to the analysis from implemented  Generally, SW-CRTs stepped-wedge trials have a minimum of 
3 sequences. Trials with 2two sequences and three3 periods, for example, a two-arm before and after cluster 
randomizsed trials in which both arms are initially observed under the control condition and in addition , in which 
the control arm adopts the intervention during a third measurement period  and there is a third measurement 
period in the intervention condition in both arms might also technically be considered a  SW-CRTstepped-wedge 
trial. The statement was developed for comparisons of two treatment conditions. So as to take a broader 
perspective on the range of designs that can be included, we are not restricting our definition to designs with all 
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clusters initiating in the control condition and ending up in the intervention condition [Hooper 2016], so include 
recent proposed dog-leg designs and variations [Hooper 2015].  
A wide variety of terminology has been used to describe aspects of the SW-CRT design. For the purpose of this 
reporting statement, the key components of the design are defined in Figure 1 and a glossary of terms is provided in 
Table 1.  
Extending the CONSORT statement to SW-CRTs  
We developed this extension using methods recommended for developing reporting guidelines [Moher 2010]. We 
registered our protocol on the EQUATOR website in July 2015 [Hemming 2015c] and identified relevant and related 
reporting guidelines. We conducted several systematic reviews of published SW-CRTs examining aspects of reporting 
and methodological conduct and undertook a consensus process.  
Results from systematic reviews examining SW-CRT methods and reporting  
We conducted several systematic reviews in advance of the consensus process [Martin 2016; Taljaard 2017; Grayling 
2017; Martin 2017]. Martin et al. (2016) found that the SW-CRT is increasingly being used and that the majority of 
trials are conducted in advanced economies and in healthcare settings; although a significant minority are conducted 
in lower middle income settings; with most trials having less than 20 clusters and a smaller number of time periods 
[Martin 2016].  
Reviews of the quality of reporting of sample size and analysis methods revealed incomplete or inadequate reporting 
overall, and specifically, lack of reporting of how time effects and extended correlation structures were incorporated 
both at the design and analysis stages [Davey 2015; Martin 2016; Grayling 2017; Martin 2017]. Reviews of the ethical 
conduct and reporting revealed that many SW-CRTs do not report research ethics review; do not clearly identify 
from whom and for what consent was obtained; and a significant number do not pre-register with a trial registration 
database [Taljaard 2017]. Reviews of the methodological literature have identified several key aspects of the SW-CRT 
which are associated with bias [Barker 2016; Martin 2017]. Clear reporting of these aspects is essential to facilitate 
interpretation of trial results in published reports.  
Firstly, time is a potential confounder in a SW-CRT and requires special consideration both at the design and analysis 
stage [Hughes 2007; Hemming 2017]. Secondly, as the SW-CRT is a longitudinal and clustered study, correlation 
structures are more complex than those of a parallel CRT carried out at a single cross-section in time [Hooper 2016]. 
Thirdly, some SW-CRTs are at risk of within-cluster contamination. Within-cluster contamination can arise either 
when outcomes in the intervention condition are obtained from participants who are yet to be exposed to the 
intervention, or alternatively, when outcome assessments in the control condition are from participants already 
exposed to the intervention [Copas 2015]. Contamination arising from observations yet to be fully exposed to the 
intervention condition can be allowed for by building in transition periods into the design; or by modelling these 
effects (referred to as lag effects) [Hughes 2015]. Interactions between time and treatment can also arise. These 
time varying effects are more likely to arise when the intervention is not continuously delivered, does not create a 
permanent change, or where its impact might waiine or grow over time [Davey 2015].  
These complexities differ according to the many different ways that a SW-CRT can be conducted, including whether 
the same or different participants are repeatedly assessed, whether participants are continuously recruited and the 
duration of their exposure, and whether a complete enumeration of the cluster is taken [Hemming 2015; Copas 
2015]. With practical and ethical considerations also in play, the adoption of this design requires careful justification 
[Prost 2015; Doussau 2016]. A summary of key methodological issues which need extra consideration when 
reporting a SW-CRT is presented in Table 2.  
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Consensus process 
Members of the working group (KH, MT, JEM, AF, CW, JG) identified items from the original CONSORT statement 
which required modification; considered whether the modification used in the cluster extension was appropriate; 
and if not, proposed a modified version for the item. In a modified Delphi process (December 2016), we invited 64 
subject experts to consider, rate and comment on the proposed modifications of whom 42 completed the survey. 
We summarised responses from the survey and circulated a second draft of the proposed modifications in advance 
of a one-day consensus meeting (Liverpool May 2017). The CONSORT stepped-wedge consensus group (20 people in 
total all listed as authors of this statement) consisted of members of the working group and those with expertise in 
trial design, journal editors (BMJ Open, Trials, Clinical Trials, and BMJ Quality and Safety Improvement), ethicists, 
statisticians, methodologists, and developers of reporting guidelines (cluster trials, pilot and feasibility trials and 
equity trials). At the meeting, proposed wording, examples and elaboration text were discussed and amended. The 
proposed final wording was then circulated; and final comments incorporated. 
 
The CONSORT extension for Stepped-Wedge Cluster Randomised Trials  
A checklist detailing the 26 items to be reported in the publication of a SW-CRT is presented in Table 3. Some items 
have not been modified from the original CONSORT statement, some are modified, and some are new. Similar to the 
CONSORT extension for cluster trials, Item 10 (Implementation of randomisation) has been replaced by Items 10a, 
10b and 10c. In recognition of the under-reporting of key ethical aspects of these trials, a new item on Research 
Ethics Review has been added as Item 26 (as was added to the CONSORT extension for pilot and feasibility studies 
[Eldridge 2016]). For ease of interpretation in the elaboration that follows, we provide the original CONSORT 
wording, the wording of the CONSORT extension for cluster randomised trials, as well as the wording for the SW-CRT 
extension. Table 4 summarises key changes to the original CONSORT statement and substantial deviations from the 
CONSORT extension for cluster randomised trials. We have provided examples and explanations for most items. 
Where the item has not been modified or the modification is only minor, readers are referred to the original 
statements for full explanation and elaboration [Schulz 2010; Campbell 2012]. For some items, which have not been 
modified, an example or explanation has been provided where this item raises specific nuances under the  SW-
CRTstepped-wedge design. Given differences in terminology used to describe the SW-CRT and the significant 
number of modified items, the items in this statement have been written in such a way so as to replace the original 
CONSORT items; and therefore, should not be considered extensions to the original items.  
Title and abstract 
Item 1a Title 
Standard CONSORT item: Identification as a randomised trial in the title. 
CONSORT cluster extension: Identification as a cluster randomised trial in the title. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Identification as a stepped-wedge cluster randomised 
trial in the title. 
 
Example: “The Devon Active Villages Evaluation (DAVE) trial of a community-level physical activity intervention in 
rural south-west England: a stepped wedge cluster randomised controlled trial.” [DAVE Trial] 
 
Explanation: One reason for including the type of study design in the title is to facilitate accurate identification of 
relevant studies in systematic reviews. A wide variety of different terminology is currently used to describe the SW-
CRT. These include the "multiple-period baseline design" and the "wait list design" (although not every multiple-
period baseline design and wait list design will be a SW-CRT). Adoption of a single term will improve the 
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identification of these studies and differentiate studies which are not SW-CRTs. Reporting of parallel cluster 
randomised trials (CRT) improved with the adoption of the single term “cluster” rather than the mix of terms (such 
as “group randomised” or “field trial”) [Ivers 2011]. It can also be useful to report any trial acronym in the title, to aid 
future searches for the study.  
Item 1b: Abstract 
Standard CONSORT item: Structured summary of trial design, methods, results, and conclusions (for specific 
guidance see CONSORT for abstracts). 
CONSORT cluster extension: Abstract See Table (not shown).  
Extension for stepped-wedge trialsExtension for SW-CRTs: Structured summary of trial design, methods, results, 
and conclusions (Table 5). 
 
For the same rationale as provided in the other CONSORT statements, clear reporting of the trial’s objectives, design, 
methods, main results and conclusions in the abstract is crucial. The primary reason for this is that many readers will 
base their assessment of the trial from the information available in the abstract [Hopewell 2008]. A review assessing 
the quality of reporting of abstracts from fully published SW-CRT revealed incomplete reporting of important details 
[Wang 2017]. A set of items to be reported as a minimum in an abstract of a SW-CRT is included in Table 5. Of some 
note, the Items recommended to be reported in the abstract results section do not include the summary measures 
of the outcome under intervention and control conditions, so as to avoid misattributing the unadjusted difference to 
the treatment effect. A worked example of an abstract according to this template is provided (Table S1, Long-live 
Mothers Trial). 
Introduction  
Item 2a: Background 
Standard CONSORT: Scientific background and explanation of rationale. 
CONSORT cluster extension: Rationale for using a cluster design 
Extension for stepped-wedge trialsExtension for SW-CRTs: Scientific background. Rationale for using a cluster 
design and rationale for using a stepped-wedge design. 
 
Example 1 (Scientific background): “In 2008, the World Health Organization (WHO) introduced the Surgical Safety 
Checklist (SSC) designed to improve consistency of care. The pilot pre-/post evaluation of the WHO SSC across 8 
countries worldwide, which found reduced morbidity and mortality after SSC implementation, constituted the 
first scientific evidence of the WHO SSC effects. A number of subsequent studies to date have reported improved 
patient outcomes with use of checklists. Furthermore, checklists have also been shown to improve 
communication, preparedness, teamwork, and safety attitudes—findings that have been corroborated by a 
recent systematic review. Although checklists are becoming a standard of care in surgery, the strength of the 
available evidence has been criticized as being low because of (i) predominantly pre /post implementation 
designs without controls; (ii) lack of evidence on effect on length of stay; and (iii) lack of evidence on any 
associated cost savings. Randomized controlled trials (RCTs) are required….” [Surgical Checklist Trial] 
 
Example 2 (Rationale for cluster randomisation and stepped-wedge design): “A stepped wedge cluster 
randomised controlled design was chosen following piloting to facilitate roll out of the intervention, …, and 
prevent contamination and disappointment effects in hospitals not randomised to the intervention.” [FIT Trial] 
 
Explanation: The need for any randomised evaluation of an intervention, whether randomising clusters or individuals 
should be justified. This justification should make reference to the best available evidence for similar interventions. 
Reasons why current evidence is lacking should be articulated (as in Example 1).  
Formatted: Not Highlight
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As with any trial design, key aspects of the design should be justified. In the SW-CRT, this justification includes the 
use of cluster randomisation, the need to roll out the intervention to all clusters (where this is the case), and the 
need for staggered roll-out of the intervention [Hargreaves 2015]. Justifying cluster randomisation is important 
because cluster randomisation increases the sample size and this, in turn might expose more participants to 
interventions of unknown effectiveness. Justifying the need for a staggered roll-out of the intervention using a SW-
CRT, as opposed to a simple parallel arm implementation, is important because the SW-CRT is more complicated in 
its design, analysis, and implementation than the parallel CRT. R. Risks of bias in the SW-CRT may be higher than in a 
parallel CRT. For example, secular trends may be of concern in a SW-CRT, but not in a parallel design [Hemming 
2017]. Risks of bias arising from identification and recruitment of participants may also be higher because in a SW-
CRT it may be more difficult to blind people recruiting participants to the cluster’s allocation status. The design is 
consequently viewed by some as potentially providing a lower level of evidence compared to the parallel CRT 
[Mdege 2011; Kotz 2012; Haines 2017]).  
Some possible justifications for adopting the stepped-wedge design include that the intervention will be rolled out 
regardless of the research study [Prost 2015], availability of an inadequate number of clusters to achieve the target 
power in a parallel design [Hemming 2016], to increase statistical efficiency [Lawrie 2015; Girling 2016; Zhan 2017], 
or to facilitate recruitment when engagement of clusters is only forthcoming on some promise of the intervention 
(as in Example 2).  
Although staggering the roll-out may appeal to researchers with limited resources for delivering the intervention 
simultaneously, this is not in itself a legitimate argument for a SW-CRT [Hemming 2015b]. Providing the intervention 
to all clusters might also increase the duration of the study (due to the staggering of the roll-out) and will possibly 
increase the number of clusters (and patients) exposed to the intervention (due to all clusters receiving the 
intervention). For these reasons, justifying the need to expose all clusters (where this is the case) to the intervention 
is important. The cluster cross-over design is a more statistically efficient design than the SW-CRT and it might 
therefore be important to justify why a unidirectional cross-over design has been chosen. However, in practice the 
use of the cluster cross-over design is restricted to interventions that can be withdrawn from use, and this largely 
depends on the type of intervention being evaluated.  
Item 2b: Objective 
Standard CONSORT item: Specific objectives or hypotheses. 
CONSORT cluster extension: Whether objectives pertain to the cluster level, the individual participant level or 
both. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Specific objectives or hypotheses.  
 
Example: “We report a stepped wedge cluster RCT aimed to evaluate the impact of the WHO SSC (World Health 
Organisation Surgical Safety Checklist) on morbidity, mortality, and length of hospital stay (LOS). We 
hypothesized a reduction of 30 days' in-hospital morbidity and mortality and subsequent LOS post-Checklist 
implementation.” [Surgical Checklist Trial] 
 
Explanation: Having a clear and succinct set of objectives can help summarise the overarching aims of the study. 
Specification of the objectives gives clarity about the anticipated effects of the intervention being evaluated (as in 
Example). Sometimes these effects will be anticipated to be on process outcomes (e.g. systems changes, clinician 
performance), particularly in trials which target health care providers; other times the intervention might target 
patients and anticipate effects on clinical outcomes. One specific objective which can be of interest in a SW-CRT is to 
evaluate the effect of the intervention by timing of implementation (e.g. does the effect of the intervention change 
as the intervention is perhaps refined over time) or time since intervention implementation (e.g. does the 
intervention create a permanent effect). Also of relevance is whether the study is to show superiority of the 
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intervention condition, non-inferiority or equivalence. For non-inferiority or equivalence authors should also ensure 
reporting according to the CONSORT extension for non-inferiority and equivalence studies [Piaggio 2012].   
Methods: Trial design 
Item 3a: Trial design 
Standard CONSORT item: Description of trial design (such as parallel, factorial) including allocation ratio. 
CONSORT cluster extension: Definition of cluster and description of how the design features apply to the clusters. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Description and diagram of trial design including 
definition of cluster, number of sequences, number of clusters randomised to each sequence, number of periods, 
duration of time between each step, and whether the participants assessed in different periods are the same 
people, different people, or a mixture.  
 
Example 1: “During the DAVE study, the intervention will be rolled out sequentially to 128 rural villages (clusters) 
over four time periods. The evaluation will consist of data collection at five fixed time points (baseline and 
following each of the four intervention periods)… The intervention will be fully implemented by the end of the 
trial, with all 128 villages receiving the intervention: 22 first receiving the intervention at period 2, 36 at period 3, 
35 at period 4, and 35 at period 5.” [Dave Trial Protocol, Figure S1] 
 
Example 2: This study will use a closed cohort stepped wedge cluster randomised design, which involves a 
sequential crossover of clusters from the control to the intervention arm, so that every cluster begins in the 
control condition and eventually receives the intervention, with the order of crossover randomly determined. The 
study will be conducted in four rural villages…At the start of the study period, baseline (T0) demographic and 
health data will be collected from each consenting household and baseline hygiene education will be provided. 
…The second (T1) health survey will start 4 weeks after the initiation of piped untreated river water supply to 
evaluate the impact of hygiene education combined with improved water quantity compared with baseline (T0). 
RBF-treated water (intervention arm) will then be sequentially introduced to each village in random order at 12-
week intervals (T2–T5), with health surveys performed 4 weeks after the implementation of the intervention to 
assess the additional effects of improved water quality [Riverbank Filtration Trial, Figure 2] 
 
Explanation: The specific details of the design of the SW-CRT have implications for the type of analysis and sample 
size calculations required.  
Information on the number of sequencesteps and the number of clusters randomised to each sequence is the core 
of the study design and so should be reported. The number of time periods will often (but not always) be one more 
than the number of steps (as in Example 1). Definition of cluster (as clearly reported in Example 1) and duration of 
time periods are also crucial. The duration of the first and last periods can sometimes differ from other periods; if so, 
this should be reported. The number of clusters allocated to each sequence may vary and, if so, this should be 
reported. Also of relevance is whether the design is to show superiority of the intervention condition, non-inferiority 
or equivalence.  
Information on whether the measurements taken in the different time periods are from the same individuals or 
different individuals is important for both sample size and analysis. In an open cohort design, participants are 
repeatedly assessed over series of measurement points and participants can join and leave the cohort; in a closed 
cohort design, new participants cannot join the study; in a cross-sectional design, different participants are assessed 
at each measurement occasion. Measurements can also take place at one point in time in each period, or can be 
continuous throughout the period. This issue is covered in more detail under Item 6a (assessments of outcomes). 
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10 
 
A diagram of the trial design can efficiently communicate the details. Key points to depict in the design diagram are 
the timing of the interventions (Item 3a) and the timing of the data collection (Item 6a). In the Riverbank Filtration 
Trial, key information about the design was reported in a diagram (Figure 2) and the main text (Example 2).   
Item 3b: Changes to tTrial design 
Standard CONSORT item: Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons. 
CONSORT cluster extension: No modification suggested.  
Extension for stepped-wedge trialsExtension for SW-CRTs: Important changes to methods after trial 
commencement (such as eligibility criteria), with reasons. 
No modification suggested. 
 
Example: “…delayed Research and Development registration shortened the baseline pre-randomisation phase 
from twelve months to nine in the first hospitals randomised to the intervention.”[FIT Trial] 
 
Explanation: Changes to key features of the design can have important implications for the interpretation of results. 
Some changes or deviations may be inevitable. Potential changes in the SW-CRT include modification to the duration 
between steps (perhaps because of study set up delays as in Example). The timing of any changes is important as 
they may affect some observations / clusters and not others.  
Methods: Participants 
Item 4a: Participants 
Standard CONSORT item: Eligibility criteria for participants. 
CONSORT cluster extension: Eligibility criteria for clusters.  
Extension for stepped-wedge trialsExtension for SW-CRTs: Eligibility criteria for clusters and participants.  
 
Example: “Inclusion criteria: Institution level: At least two units of one (from each) nursing home must participate 
in the study, from which at least 30 residents with dementia can be recruited. The care of the residents must 
predominantly take place in the respective unit. Resident level: Criteria for inclusion are informed consent 
obtained from people with dementia or their legal representative; diagnosis of dementia based on the medical 
diagnosis in the charts and a FAST score > 1); residence for at least 14 days in the unit. Staff level: All of the 
nursing staff working in one of the two participating wards of the nursing home must provide their informed 
consent.” [FallDem Trial] 
 
Explanation: The SW-CRT is a type of cluster randomised trial and as such, has inclusion and exclusion criteria for 
both clusters and participants. Furthermore there may be multiple levels of participants. For example, clusters may 
be general practices that include cluster-level participants (e.g. general practitioners) and individual-level 
participants (e.g. patients). So, in some trials, there may be multiple levels at which inclusion and exclusion criteria 
apply (as in the Example). Reporting of eligibility criteria is important so that readers can infer how typical or atypical 
the clusters and participants are of the population at large [Zwarenstein 2008].  
Item 4b: ParticipantSettings 
Standard CONSORT item: Settings and locations where the data were collected. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Settings and locations where the data were collected. 
No modification suggested. 
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Readers are referred to the CONSORT statement and its extension to CRTs for examples and explanation [Schulz 
2010, Campbell 2012].  
Methods: Intervention 
Item 5: Intervention 
Standard CONSORT item: The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered. 
CONSORT cluster extension: Whether interventions pertain to the cluster level, the individual participant level or 
both. 
Extension for stepped-wedge trialsExtension for SW-CRTs: The intervention and control conditions with sufficient 
details to allow replication, including  if maintained or repeatedhow and when they were administered; whether 
the intervention was delivered at the level of the cluster, the individual, or both.  
 
Example 1 (Description of the intervention condition): “The intervention involves three key modes of delivery: 
verbally via reception staff, in paper form with a pamphlet, and electronically via a secure, internet-enabled 
tablet (see Table (not provided) for overview of intervention). First, reception staff will verify the organ donor 
registration status of patients upon their arrival at the clinic on the provincial health card that patients must 
provide to receive healthcare services from their family physician. As reception staff already request a patient’s 
health card during their visit, this step is designed to fit within existing work routines rather than increasing any 
workload. Reception staff will provide patients that have not yet registered with an educational pamphlet 
including a photo and signature of the physicians in the office and office logos and include messages that directly 
address identified barriers to donor registration. Second, internet-enabled tablets will be provided in each waiting 
room to give patients the immediate opportunity to register for organ donation online via a secure provincial 
website. The location of the materials will be tailored according to the family physician office’s preferences.” 
(further details provided in paper) [RegisterNow-1 Trial] 
 
Example 2 (Description of control condition): “If the participant’s medical centre is in the control phase, they will 
receive usual care. In Australia, usual care would mean the patient would consult their GP as per normal 
standards for that practice for a patient discharged from hospital. There will be no pharmacist in the medical 
centre during the control phase. Medication liaison in the form of a discharge medication record may be provided 
to patients on discharge from hospital and may be included in the hospital discharge summary to the GP.” 
[REMAIN Trial Protocol] 
 
Example 3 (Unit of delivery is individual): “The intervention comprised a therapeutic dose of AQ (10 mg/kg/day 
for 3 days) combined with one dose of SP on the first day (25mg sulfamethoxypirazyne and 1.25mg 
pyrimethamine per kg in 2008, 25mg sulfadoxine, 1.25mg pyrimethamine in 2009–10) administered once per 
month for the last three months of the malaria transmission season (September-November).” [SMC Trial] 
 
Example 4 (Continuously delivered intervention): “It (the intervention) comprised bedside placement of alcohol 
hand-rub, posters and patient empowerment materials encouraging healthcare workers to clean their hands, plus 
audit and feedback of hand-hygiene compliance at least once every 6 months.” [FIT Trial] 
 
Explanation: Clear reporting of the intervention is essential to allow replication and implementation of successful 
interventions (Example 1). For interventions demonstrated to have little evidence of benefit, reporting of sufficient 
detail of the intervention helps to avoid evaluating the same intervention again or to identify what aspects of the 
intervention could be modified. This is especially important for complex interventions – a common type of 
intervention evaluated in SW-CRTs. We recommend reporting details of the intervention as per the TiDierR guideline 
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[Hoffmann 2014].  As per the original CONSORT statement, it is important to describe all treatment conditions being 
compared. In SW-CRTs the comparator is often "usual care" which should be described in sufficient detail (Example 
2). The control condition should be described in a similar level of detail to the intervention condition [Zwarenstein 
2008].  
Information on whether the intervention is delivered at the level of the cluster or individual (or perhaps both) is 
important as it allows identification of whether individuals can avoid the intervention. For example, an intervention 
which is delivered at the level of the cluster will often mean that it is delivered to all individuals within that cluster 
(Example 1). In the SMC Trial the intervention was delivered directly to the individual (Example 3). This information is 
also important as it can inform the degree of penetration of the intervention and it can also be helpful in eliciting 
what consent procedures should be in place (Items 10c and 26).  
In a SW-CRT it is important to be clear about whether the intervention is expected to create an effect that is 
expected to be immediate (or delayed); and whether the anticipated effects of the intervention are expected to be 
sustained. This is important because the observations contributing to the analysis will consist of a mixture of 
observations collected immediately after roll-out of the intervention; and observations collected some time post 
roll-out.  
The effect of any intervention can be delayed; for example, due to a learning effect, one may need to allow for a 
delay before the effect is fully realised (this might perhaps be the case in Example 4). In these situations a transition 
period might be incorporated into the design. Furthermore the anticipated effects of the intervention might be 
sustained (in which case an intervention might be designed to have a one-off delivery, as in Example 1) or expected 
to decay (in which case an intervention might be designed to have repeated delivery, as in Example 4). In some SW-
CRTs the exact form of the intervention may evolve over time; reporting this information allows assessment of the 
level of standardisation of the intervention across the clusters [Zwarenstein 2008]. 
In Example 1 the intervention being evaluated is formed of several components. Depending on the format of the 
different components, in some studiesThis this might mean there may be both a delay before any anticipated effect 
is realised; and it might be the case that the effects of some components might waine through familiarity. 
Furthermore some some components of an the intervention  in Example 1 might beare continuously delivered (i.e. 
provision of pamphlets) whereas some components might be are delivered just once (i.e. educational components). 
In Example 4 it is the educational component of the intervention is re-enforced and so its anticipated effect is less 
likely to decay.  
Methods: Outcomes 
Item 6a: Outcomes 
Standard CONSORT item: Completely defined pre-specified primary and secondary outcome measures, including 
how and when they were assessed. 
CONSORT cluster extension: Whether outcome measures pertain to the cluster level, the individual participant 
level or both. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Completely defined pre-specified primary and 
secondary outcome measures, including how and when they were assessed.  
 
Example 1 (Pre-specified outcomes): “The primary outcome of the study is a 7-day period prevalence of diarrhoea 
among villagers of all ages. Secondary outcomes include a 7-day period prevalence of other hygiene-related 
illnesses (respiratory and skin infections), reported changes in hygiene practices, household water usage and 
water supply preference.” [Riverbank Filtration Trial] 
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Example 2 (Cross-sectional sampling): “Data collection for the evaluation took the form of a postal survey 
conducted at five fixed time points: baseline (in the month prior to commencement of the first intervention 
period) and within a week of the end of each of the four intervention periods. A repeated cross-sectional design 
was employed, in which a random sample of households within each cluster was selected to receive the survey at 
each period.” [DAVE Trial] 
 
Example 3 (Cohort design): “All household members will be eligible for inclusion in the study, regardless of age. 
…Each household will have the option to participate in up to five subsequent surveys…Outcomes will be 
measured at each of the six survey visits.” [Riverbank Filtration Trial] 
 
Example 4 (Transition period): “A 1-month transition phase is included where the medical centre is not 
considered as being in control or intervention and does not contribute to analysis. This transition period allows 
for the time it takes to embed the intervention into a medical centre.” [REMAIN Trial] 
 
Example 5 (Time to assessment and source of data): “Participants will be followed up to 12 months from day of 
hospital discharge. This will be done through collection of routine data from the hospital and medical centre. 
Demographics and reason for admission at enrolment and subsequent admissions in the 12-month follow-up will 
be collected through participant hospital records…Medical centre records will be used to identify whether a 
discharge treatment plan was received and the timeliness and number of GP visits during the 12-month follow-up 
period for each participant.” 
 
Explanation: All outcomes should be completely defined. This should include the pre-specified primary outcome and 
all secondary outcome measures (Example 1). It is also important to report clearly how and when these 
measurements were obtained. 
SW-CRTs make a series of measurements over time within each cluster. These measurements could be on different 
participants in each period (i.e. cross-sectional design) as in Example 2; the same participants (i.e. cohort design) as 
in Example 3; or a mixture, and this will inform the method of analysis and has implications for sample size 
calculations. Data are rarely collected at the level of the cluster, but knowledge of whether outcomes in each period 
are at the cluster level (either because of true cluster level outcomes or because of the availability of aggregated 
data only) or individual level has implications for the method of analysis. 
It should be reported whether outcomes are collected at discrete points in time common to all participants (e.g. a 
survey implemented at several discrete points in time as in Example 3), or at time points specific to each participant 
(e.g. as they leave hospital as in Example 5). The timing of measurements has implications for the choice of analysis. 
For example, if the outcomes are collected at discrete time points (as in Example 3), then time effects can be 
included as categorical effects; whereas if the outcomes are collected continuously (for example as would be the 
case in a SW-CRT where the outcome was routinely collected mortality data), then time effects could potentially be 
modelled using parametric or semi-parametric forms.  
The reporting of the timing of data collection should also note whether there were periods in which outcomes were 
not ascertained, for example transition periods immediately after the intervention was rolled out, to allow time for 
the intervention to realise its full impact (as in Example 4).  
In individually and cluster randomised parallel trials outcomes are often assessed at multiple time points (for 
example 6 and 12 months post randomisation) and it is important to pre-specify the primary follow-up time of 
interest. This might also be the case in SW-CRTs. Sometimes the outcome assessments will extend beyond the actual 
study dates. For example, a trial might roll-out the intervention to clusters over a four year period and the primary 
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follow-up time might be 30 years later [Shimakawa 2014]. Clear reporting on the timing of follow-up assessments (as 
in Example 5) also allows assessment of whether all observations collected under the intervention condition were 
fully exposed to the intervention, and whether any observations collected under the control condition might have 
been contaminated by the intervention.  
Reporting whether data were collected from routine sources or purposively collected can help ascertain the risk of 
bias (e.g. from measurement of the outcome) and identify who are the human research participants (see Item 26). 
SW-CRTs are often implemented in real-world settings and, as such, may rely on routinely collected outcome data 
(Example 5). Reporting of whether the data collection procedures changed over time is important given the 
imbalance over time with respect to intervention conditions [Shadish 2002]. It is also important to report ; and any 
measures which can allow assessment of the reliability and validity of routinely collected data.  
Methods Outcomes 
Item 6b: Changes to outcomes 
Standard CONSORT item: Any changes to trial outcomes after the trial commenced, with reasons. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Any changes to trial outcomes after the trial 
commenced, with reasons. 
No modification suggested. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Methods: Sample size 
Item 7a: Sample size 
Standard CONSORT item: How sample size was determined. 
CONSORT cluster extension: Method of calculation, number of clusters(s) (and whether equal or unequal cluster 
sizes are assumed), cluster size, a coefficient of intra-cluster correlation (ICC or k), and an indication of its 
uncertainty. 
Extension for stepped-wedge trialsExtension for SW-CRTs: How sample size was determined. Method of 
calculation and relevant parameters with sufficient detail so the calculation can be replicated (Table 6). 
Assumptions made about correlations between outcomes of participants from the same cluster.  
 
Example 1 (Sample size): “We would consider an absolute increase of 10% in the proportion of patients who are 
registered organ donors at 7 days post-encounter to be both clinically important and feasible. Our sample size of 
6 clusters (10,500 patients in total) achieves 80% power to detect this difference assuming a control proportion of 
0.5 using a two-sided test at the 5% level of significance [Hooper 2016]. Our calculation assumes an intra cluster 
correlation coefficient of 0.06, as calculated from our previous work (19), an average of 250 patient encounters 
per site in each two-week interval, and a cluster autocorrelation coefficient of 0.8 to allow for a 20% decay in the 
strength of the correlation in repeated measures over time.(20) The percentage of registered donors in the 
control condition is conservatively assumed to be 50% to allow for a higher prevalence of registered donors in our 
participating offices than the provincial average. No adjustment is made for cluster attrition as the risk of attrition 
is low, and all outcomes will be assessed from routinely collected sources, regardless of any drop-out. Given some 
uncertainty around parameter estimates required for the stepped wedge sample size calculation, sensitivity of 
our detectable effect size to a range of alternative assumptions is presented in Table (not shown). The results 
show that across a range of control arm proportions (from 0.4 to 0.5), average cluster sizes (from 100 to 400), and 
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cluster autocorrelation coefficients (from 0.8 to 0.95), our sample size of 6 practices will achieve 80% power to 
detect absolute increases between 5% and 11%.” [RegisterNow-1 Trial] 
 
Example 2 (Sample size fixed by design): “The study had a fixed sample size by design that could not be modified, 
so the power calculations did not inform any sample size targets.” [Targeted Case Finding Trial] 
 
Explanation:  
The  method of calculation and all relevant parameters, used in the sample size calculation should be given. Most of 
the key items to report are listed in Table 6. These have been divided into key items which are essential and likely of 
relevance to all SW-CRTs; and those which might be considered additional or supplementary information which will 
only be of relevance to some SW-CRTs. Besides the usual effect size, significance level and power, these  may 
include: the cluster size and whether account of  unequal cluster sizes has been made, avoiding any ambiguity 
between cluster size per measurement period and total cluster size; a within-period intra-cluster correlation (ICC) 
and assumptions about correlations between outcomes of  different  participants from the same cluster in different 
periods (or other assumptions which appropriately reflect the complexity of the design); allowance for repeated 
measurement taken from the same participants,   with sufficient detail to allow the calculation to be 
replicated.  Often a sensitivity analysis, looking at the effect of relaxing some of the assumptions, may be warranted.  
Specifying the method of sample size calculation [Hussey 2016; Hooper 2016], or providing access to sample size 
calculation code [Baio 2015; Hooper 2016; Hemming 2016] or programmed sample size function [Hemming 2014] 
can aid replication of the sample size (Example 1 reported they used the Hooper method). Detailed reporting of the 
sample size method will allow assessment of whether the method has allowed for all features inherent to the 
particular design (e.g. transition periods, repeated measures on the same participants). Reporting of the sample size 
calculation will likely include: number of clusters and whether equal or unequal cluster sizes are assumed, cluster 
size or cluster size per period, number of sequences, and number of clusters per sequence. Reporting of these basic 
sample size elements is poor in SW-CRTs [Martin 2016]; as is the reporting of basic elements in parallel CRTs 
[Rutterford 2015].  
For clarity it is important to distinguish between total cluster size (across all periods) and cluster sizes per period 
(Example 1). In a design which repeatedly measures the same participants it would be natural to provide the number 
of participants in each cluster and the number of repeated measurements per participant; in a design which involves 
taking repeated, discrete samples with different participants each time it would be natural to provide the number of 
participants in each cluster in each of these periods; whereas in a design where newly eligible individuals are 
recruited continuously it might be more appropriate to report the total number of participants expected in each 
cluster over the duration of recruitment. 
In a parallel CRT it is important to report the intra-cluster correlation coefficient (ICC) (the correlation between 
outcomes of two individuals from the same cluster). The coefficient of variation of cluster rates, proportions or 
means has been suggested as an alternative parameter in sample size formulae for CRTs [Hayes 1999]. Correlation 
structures are more complicated in a SW-CRT and there may not be a single ICC, as the strength of correlation might 
depend additionally on the separation in time [Hooper 2015; Martin 2016b; Kasza 2017]. Such correlation structures 
could be formalised in a variety of ways, for example using a within-period ICC and a between-period ICC or cluster 
auto-correlation coefficient (as in Example 1) [Kasza 2017]. In SW-CRTs where the same individuals are assessed 
repeatedly it may also be important to consider correlations over time within individuals [Hooper 2016].    
An indication of the sensitivity of the sample size or power to the assumed parameter values could be provided, for 
example, by reporting sample size or power at a variety of alternative correlation values. Rationale for the assumed 
parameter values should be provided (as in Example 1).  
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In randomised trials the sample size (and so consequently the number of clusters) is often based on the number 
needed to detect the target difference at a desired level of power and significance [Cook 2017]. SW-CRTs can 
sometimes have their sample size fixed by the number of clusters, participants, or both, available in a natural setting. 
Whether the sample size was fixed by factors outside of the control of the experimenters or based on the target 
difference (as conventionally is the case in a randomised controlled trial) should be reported (as in Example 2). When 
the sample size is fixed, it can be useful to report what effect size the study was powered to detect. If no power 
calculation was performed, this should be reported. Retrospective power calculations based on the results of the 
trial are of little merit [Hoenig 2001; Sculz 2010].  
Item 7b: Interim analyses 
Standard CONSORT item: When applicable, explanation of any interim analyses and stopping guidelines. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: When applicable, explanation of any interim analyses 
and stopping guidelines. 
No modification suggested.  
 
Explanation: Interim analyses of outcomes can be used to assess harm, futility, and efficacy. Interim analyses can 
also be used to monitor recruitment and retention rates, and monitor balance across control and intervention 
conditions (where trial processes suggest that there may be a risk of differential recruitment or consent).  
The relevance of interim analyses of outcomes might be questionable in some SW-CRTs, so careful reporting of 
motivation is important. For example, if the intervention is being rolled out to all clusters within the fastest time 
frame possible, then stopping the trial early after demonstrating efficacy does not necessarily mean the intervention 
can be rolled out to the remaining clusters immediately. In some settings, SW-CRTs evaluate interventions for which 
safety concerns are likely to be minimal (although this will not always be the case). It might be of interest to consider 
stopping a SW-CRT for futility, although if there are minimal safety concerns then stopping the trial early for futility 
may also not be worthwhile. However, other important reasons for considering stopping a trial include that the trial 
itself is not successful, perhaps because clusters are failing to adhere to the randomisation schedule, because data 
for outcomes are not forthcoming, or because procedural requirements have delayed the start dates for many 
clusters [Kristunas 2017]. Dates or times at which any interim analysis will be carried out should be reported 
together with objectives of such interim analyses.  
Of note, in a SW-CRT due to the imbalanced nature of the design, interim analyses for outcomes carried out early in 
the trial will have a large imbalance between numbers of observations exposed to control and intervention 
conditions. This imbalance is likely to have power implications [Grayling 2017]; and will make a blinded interim 
analysis infeasible. The clustered nature of the data will also have implications on power and interim analyses [Zou 
2005]. Proposed methods of interim analysis should be outlined. Interim analyses of outcomes might or might not 
follow the same method of analysis planned for the main results. As with any trial, incorporation of any interim 
analyses of outcomes (where a decision is to be made about continuation of the trial) should be allowed for in power 
calculations to control for the over-all Type I error rate. 
Methods: Randomisation – Sequence generation  
Item 8a: Sequence generation 
Standard CONSORT item: Method used to generate the random allocation sequence. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Method used to generate the random allocation to the 
sequences of treatments.  
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Example: “Eligible schools were randomly assigned to one of the four sequences (3 or 4 schools per sequence) for 
time of crossover from control to intervention using a computer-generated list of random numbers.” [SBP Trial] 
 
Explanation: Random allocation in SW-CRTs takes a different form to that in parallel arm designs. Rather than each 
cluster being randomly allocated to one of two treatments, allocation is to one of several sequences which define 
the order with which clusters cross from the control condition to the intervention condition (Example). The term 
“sequence generation” in a SW-CRT therefore has a slightly different meaning to that of individually randomised 
trials. In an individually randomised trial “sequence” refers to a sequence of treatments to allocate all participants to 
either the intervention or control condition.  
Furthermore, rather than the randomisation being performed as clusters or individuals present to the trial the 
randomisation in a SW-CRT is usually done at a single point in time before the trial starts.  
Methods Randomisation – Sequence generation 
Item 8b: Randomisation methodSequence generation 
Standard CONSORT: Type of randomisation; details of any restriction (such as blocking and block size). 
CONSORT cluster extension: Details of stratification or matching if used 
Extension for stepped-wedge trialsExtension for SW-CRTs: Type of randomisation; details of any constrained 
randomisation or stratification if used. 
 
Example 1 (Unrestricted): “Nursing-home units were the unit of randomisation... RL (not involved in recruitment) 
randomly allocated units to one of five groups with computer-generated random numbers…” [Depression 
Management Trial] 
 
Example 2 (Stratification): “All schools are assigned a decile rating, which indicates the extent to which the school 
draws its students from a range of socioeconomic areas. Decile 1 schools are the 10% of schools with the highest 
proportion of students from low socioeconomic resource areas (defined according to residents' income, 
occupation, household crowding, educational qualifications and income support) and decile 10 are the 10% of 
schools with the highest proportion of students from high socioeconomic areas…. The order of switch-over is 
determined randomly for each group (decile) of clusters” [SBP Trial Protocol] 
 
Example 3 (Covariate constrained randomisation): “The randomization was conducted using a highly restricted 
randomization design. With this limited number of randomization units, selection of one sequence from the 5.4 
*10
26
 completely at random would run the risk of obtaining a sequence that is substantially unbalanced with 
respect to one or more potentially important covariates. Randomization was done using a highly restricted 
randomization design to achieve close balance with respect to clinic-level covariates including mean CD4 count, 
clinic size, average education, tuberculosis treatment levels, existence of a supervised tuberculosis therapy 
(DOTS) program and geography (reference cited to detailed methods)”. [THRio Trial Protocol] 
 
Explanation: In a SW-CRT, rather than the randomisations being done sequentially (as the patient or cluster presents 
to the trial), the randomisation is usually done at a single point in time before the trial starts. This means that 
different methods for controlling balance of cluster-level factors can be considered along with methods used in 
individually randomised trials such as minimisation and stratification [Ivers 2012]. How the randomisation is 
restricted is known to have implications for analysis.  
There are two common ways in which clusters may be allocated in a SW-CRT. One is simple unrestricted allocation to 
one of several possible sequences (Example 1); another is stratified allocation with clusters divided into distinct 
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strata prior to random allocation within each stratum (Example 2). For a stratified design the sequences are 
generated independently within each stratum. This essentially means that separate mini SW-CRTs are conducted in 
each stratum (Example 2). Yet another method of allocation is covariate constrained allocation which balances key 
covariate values (such as cluster size) between intervention and control conditions (Example 3) [Moulton 2007].  
Methods Randomisation –Allocation concealment 
Item 9: Allocation concealment 
Standard CONSORT item: Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until interventions were assigned. 
CONSORT cluster extension: Specification that allocation was based on clusters rather than individuals and 
whether allocation concealment (if any) was at the cluster level, the individual participant level or both.  
Extension for stepped-wedge trialsExtension for SW-CRTs: Specification that allocation was based on clusters; 
description of any methods used to conceal the allocation from the clusters until after recruitment.  
 
Example 1 (Concealment from cluster): “Once 14 medical centres have provided consent to be involved in the 
study, each enrolled medical centre will be randomised to a transition step.” [REMAIN Trial] 
 
Example 2 (Concealment of cross-over date):“The allocation sequence will only be made available to two study 
investigators (ABF and MS). Indian study investigators will be blinded to the allocation sequence with only the 
next village randomised for rollout being revealed at each intervention implementation time point. Study 
participants will be blinded to the allocation sequence and those not yet receiving the intervention will not be 
aware of the time at which they will have the intervention implemented.” [Riverbank Filtration Trial] 
 
Explanation: In a SW-CRT clusters are allocated to a sequence of treatments, so clusters will spend time in the 
control condition until a particular date when they cross to the intervention condition. This is unlike a parallel arm 
cluster randomised trial in which clusters are allocated to treatment conditions. Randomisation of all clusters (to 
sequences) in a SW-CRT will often occur at a single point in time (as in Example 1). Randomisation could in theory 
also be performed at step-times, where one or more of the remaining clusters will be randomly selected to cross 
over just prior to the cross-over date (no examples of this have been identified). 
It is important to report any method that was used to conceal the allocation from clusters and from those individuals 
responsible for recruiting clusters, until after recruitment. Reporting of this information allows assessment of the 
potential for selection bias [Higgins 2016]. One common way of preserving allocation concealment is to perform the 
randomisation after recruitment of all clusters (as in Example 1).  
When randomisation of the clusters occurs at a single point, the cross-over date may be revealed immediately to 
each cluster, or revealed sequentially to the clusters as they approach the time of cross-over (as in Example 2). 
Reporting when clusters were told of their cross-over date allows assessment of potential biases. For example, when 
clusters are informed of their date of cross-over at the beginning of the trial, some clusters (e.g., those randomized 
to cross over later) may drop-out, leading to differential attrition; yet at the same time a public randomisation at the 
start of the trial may also prevent subversion of the randomisation process [Higgins 2016]. Knowledge of when a 
cluster is crossing over could lead to other biases, for example, if individuals within a cluster are aware of the 
impending cross-over, they may defer enrolling participants into the trial to ensure they receive the intervention.  
Full transparency of reporting of the blinding throughout the trial, including the randomisation process, is best 
reported using a timeline diagram [Caille 2016].  
Methods: Methods Randomisation – Implementation  
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Item 10: Implementation of randomisation  
Standard CONSORT item: Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions. 
CONSORT cluster extension: Replace by 10a, 10b and 10c. 
Extension for stepped-wedge trials: Replace by 10a, 10b and 10c. 
 
Explanation: As with a parallel CRT, it is important that all steps in the implementation of the randomisation process 
are clearly described. It is important that this information on the allocation and recruitment process is described for 
both clusters and participants. Information on the allocation and enrolment of the clusters is described in Item 10a 
and corresponding information for participants in Item 10b. Enrolment of participants is closely linked to the consent 
process (for example, differential consent processes can have implications for selective recruitment). Therefore, 
following the cluster CONSORT extension, Item 10c describes the consent processes.  
Of note, we use the term “selection bias” to refer to any process by which there is differential inclusion of 
participants in the treatment conditions being compared. Sometimes selection bias is used to refer only to 
differential inclusion of clusters by intervention conditions. More specifically, “identification bias” refers to biases 
which are induced by differential application of the inclusion / exclusion criteria [Higgins 2016]. The term 
"recruitment bias" refers to biases which are induced by differential recruitment into the trial by the health care 
practitioner or to biases induced by individuals differentially declining to participate.  
Methods Randomisation – Implementation  
Item 10a: Inclusion of clustersmplementation 
Standard CONSORT item: Not included in original CONSORT statement. 
CONSORT cluster extension: Who generated the random allocation sequence, who enrolled clusters, and who 
assigned clusters to interventions. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Who generated the randomisation schedule, who 
enrolled clusters, and who assigned clusters to sequences.  
 
Example: “We will recruit a convenience sample of practices from within our network of family physician office 
contacts within the London, Ontario and Stratford, Ontario communities. A collaborating family physician will 
send an introductory email to potential family physician contacts, inviting them and their practice to consider 
participating. We will then arrange an in-person meeting with family physicians from interested sites to introduce 
our study and obtain written agreement from family physicians and offices agreeing to participate that meet our 
eligibility criteria. A statistician blinded to cluster identity and not involved in the intervention delivery will 
generate the allocation sequence using computer-generated random numbers.” [RegisterNow-1 Trial] 
 
Explanation: Knowledge of who implemented the randomisation procedures at the level of the cluster is required for 
ascertaining if selection biases are possible.  
It is important to have a separation of roles between those who generate the randomisation schedule and those 
who recruit, enrol and assign clusters to the sequence (as in the Example). If the person who generated the 
randomisation was also responsible for recruiting the clusters, this could mean that there was an increased risk of 
selection bias. This is best achieved by having a person independent of the trial doing the randomisation. This will be 
less important in trials where the randomisation takes place after recruitment of all clusters.  
Methods Randomisation – Implementation  
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Item 10b: Inclusion of participantsmplementation 
Standard CONSORT item: Not included in original CONSORT statement. 
CONSORT cluster extension: Mechanism by which individual participants were included in clusters for the 
purposes of the trial (such as complete enumeration, random sampling). 
Extension for stepped-wedge trialsExtension for SW-CRTs: Mechanism by which individual participants were 
included in clusters for the purposes of the trial (such as complete enumeration or random sampling; continuous 
recruitment or ascertainment, or recruitment at a fixed point in time), including who recruited or identified 
participants. 
 
Example 1 (Complete enumeration with continuous ascertainment): “The study included all patients admitted to 
16 acute adult wards of one general hospital over a 32-week period.” [Critical Care Outreach Trial] 
 
Example 2 (Random sampling): “Data collection for the evaluation study will focus on adults aged 18 years and 
over. The study will use a repeated cross-sectional design, in which a random sample of people within each 
cluster will be surveyed at each stage. A complete list of all households in each of the 128 study villages will be 
obtained using the Postcode... The order in which households are approached to participate in the survey at each 
stage will be randomly generated...One adult per household will be randomly selected.” [DAVE Trial Protocol] 
 
Example 3 (Continuous recruitment): “Then, the leaders of the nursing homes are responsible for the recruitment 
of the units and the residents according to the inclusion and exclusion criteria of the study. Here, all eligible 
participants of the participating units are invited to participate. Before the recruitment procedure will commence, 
each leader of the nursing homes will attend a kick-off meeting held by a senior investigator about the inclusion 
and exclusion criteria and the planned recruitment strategy. For the participants who drop out of the trial, we are 
planning to monitor the reasons (for example, death or moving) and perform a sensitivity analysis at the end of 
the trial to determine whether they differ according to certain characteristics (for example, the prevalence of the 
challenging behavior or gender). Residents who are newly admitted to clusters during follow up will also be 
included in the study …” [FallDem Trial] 
 
Explanation: Individual participants can be included in a SW-CRT in many different ways. Sometimes, participants are 
not recruited into a trial, but rather their data are used from routinely collected sources (Example 1). In this case it is 
common to take a complete enumeration of the cluster or at least those meeting the eligibility criteria. Alternatively, 
a sample of individuals from the cluster might be asked to complete data assessments or questionnaires in each 
period (Example 2). Alternatively, participants might be recruited to participate in the trial. This recruitment might 
take place continuously (Example 3) or at a fixed point in time before the start of the trial.  
Knowledge of how participants are included in the trial can help assess the likelihood of identification and 
recruitment bias. Trials with complete enumeration are less likely to suffer from these biases (Example 2). Where 
participants are identified or recruited after randomisation (as in Examples 1 and 3), either a complete enumeration 
of the cluster or recruitment/identification by someone who is blind to allocation can help mitigate recruitment and 
identification biases. Therefore, clear reporting of who recruited or identified participants and whether or not such 
individuals were blind to allocation is important so readers can determine the risks for bias. Identification and 
recruitment biases will not occur in designs in which participants are recruited prior to randomisation.  
Methods Randomisation – Implementation  
Item 10c: Consent Implementation 
Standard CONSORT item: Not included in original CONSORT statement. 
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CONSORT cluster extension: From whom consent was sought (representatives of the cluster, or individual cluster 
members, or both), and whether consent was sought before or after randomisation. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Whether, from whom and when consent was sought 
and for what; whether this differed between treatment conditions.  
 
Example 1 (Individual-level consent): “Written informed assent was obtained from all participating children as 
well as parental consent. Only children who provided both assent and parental consent were eligible to take 
part.” [SBP Trial] 
Example 2 (Cluster and individual-level consent): “Criteria for inclusion are informed consent obtained from 
people with dementia or their legal representative.…All of the nursing staff working in one of the two 
participating wards of the nursing home must provide their informed consent” [FallDem Trial] 
 
Explanation: Obtaining informed consent for participation, study interventions, and data collection procedures in 
clinical trials is an integral principle of research thics and international human rights law [IEHR 2016; UN 1966]. The 
process by which consent was obtained can lead to biases [Campbell 2012]. It is important to describe what consent 
was for (e.g. exposure to the intervention or use of data), whether consent was sought before or after 
randomisation, and whether the type of consent differed between intervention and control conditions.  
In SW-CRTs there can be cluster-level research participants (e.g., health-care practitioners) and individual-level 
research participants (e.g. patients) [Taljaard 2013]. It is therefore important to identify explicitly from whom 
consent was obtained in the study (Example 2) or to state that consent was not obtained. Furthermore, in most 
cluster trials someone provides access to the cluster; such individuals are often called “gatekeepers” or “cluster 
guardians” [Edwards 1999]. Gatekeeper permission for trial participation is different to consent from cluster-level 
research participants, such as health providers, for their own participation in the study. 
In cluster randomised trials in which the treatment is delivered at the level of the cluster, it may not be possible to 
obtain consent for exposure to the intervention or control condition as the intervention may be impossible to avoid 
(as would be the case in Example 1 under Item 10b); however, consent can still be taken for use of data (implied by 
return of questionnaire data in Example 2 under Item 10b). It is therefore important to clearly report what consent 
was for. If participants recruited to the control and intervention conditions are given different information when 
their consent is taken, this can lead to bias [Eldridge 2005]. The information provided about the objectives of the 
study can itself prompt participants to act differently. For example, participants enrolled in a study of an intervention 
to increase uptake of HIV screening, who are fully informed about the objectives of the study, might increase uptake 
of screening irrespective of allocation to the intervention condition. This is known as the Hawthorne effect 
[McCarney 2007]. Reporting what information was provided to participants can allow readers to judge the risks of 
such biases. A recent systematic review found that of the small number of SW-CRTs that reported whether or not 
consent was obtained, only a small proportion reported explicitly what this consent was for, and none reported 
when the consent was taken [Taljaard 2017].  
Sometimes a research ethics committee might deem it appropriate that the study proceed without the informed 
consent of research participants (i.e. a waiver of consent) or the research ethics committee may otherwise modify 
informed consent requirements (i.e. modification of consent). When a waiver or modification of consent has been 
granted by a research ethics committee, it should be reported and a justification given. It should be clear whose 
consent was waived and whether the waiver pertains to study participation, data collection, or both. Not all 
jurisdictions allow for a waiver or modification of consent. Information on data collection procedures in the trial, 
e.g., whether data are anonymous or pseudo-anonymous, and whether they were routinely collected, can provide 
clarity around ethical aspects of the trial. When appropriate it can be useful to include any participant consent forms 
in appendices, which will allow readers to infer precisely the information provided to participants.  
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Methods: Blinding 
Item 11a: Blinding 
Standard CONSORT item: If done, who was blinded after assignment to interventions (for example, participants, 
care providers, those assessing outcomes) and how. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: If done, who was blinded after assignment to 
sequences (for example, cluster level participants, individual level participants, those assessing outcomes) and 
how. 
 
Example 1 (Blinding not possible): “Blinding to the intervention (i.e., the type of water being received) is not 
possible due to potential differences in turbidity of untreated and RBF (Riverbank Filtration)-treated river water.” 
[Riverbank Filtration Trial] 
 
Example 2 (Blinding partially possible): “Residents did not know when the intervention was being implemented or 
what the programme elements were. Interviewers who administered the outcome questionnaires were masked 
to intervention implementation or depression treatment, and to previous test results. Data analysts were masked 
to whether a specific resident had been exposed to the intervention and to when the intervention was 
implemented in a unit, but were not masked during post-hoc analyses.” [Depression Management Trial] 
 
Explanation: SW-CRTs are often used to evaluate interventions for which it is impossible to blind participants or 
clusters to whether they are in the intervention or control condition, but nonetheless it is important to report clearly 
whether or not blinding was used and if so, who exactly was blinded to aspects of the trial (Example 1).  
Often outcomes are collected at multiple levels (e.g. hospitals (e.g. team climate outcomes), clinicians (e.g. 
knowledge, skills, practice outcomes), patients (e.g. pain)). The possibility of blinding may be different depending on 
the level of participants (e.g. clinicians or patients) and may depend on the type of consent required (Item 10c). The 
degree of blinding should be reported at each level of the trial (e.g. clusters, participants as in Example 2) and 
whether the blinding differed in control and intervention conditions. Researchers should also specifically report 
blinding with respect to all outcomes. Blinding of those assessing outcomes should be clearly reported.  
A systematic review has found that most SW-CRTs do not report clearly who was blinded and what people were 
blinded to [Taljaard 2017]. Whether or not and who was blinded, and when, is best reported by the use of a timeline 
diagram [Caille 2016].  
Item 11b: Blinding 
Standard CONSORT item: If relevant, description of the similarity of interventions. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: If relevant, description of the similarity of treatments. 
No modification suggested. 
 
Explanation: In trials with a placebo it is important to provide evidence of the similarity of the control condition to 
the intervention condition (i.e. to provide evidence of the blinding). However, In SW-CRTs it would be unusual to 
have a placebo and often participants are not blind to their allocation status. Sometimes, a minimal level of 
intervention is provided in the control condition in an attempt to keep participants blinded to their status as 
intervention or control participants. When appropriate such minimal level interventions should be described in full. 
Methods: Statistical methods 
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Item 12a: Statistical methods 
Standard CONSORT item: Statistical methods used to compare groups for primary and secondary outcomes. 
CONSORT cluster extension: How clustering was taken into account. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Statistical methods used to compare treatment 
conditions for primary and secondary outcomes including how time effects, clustering and repeated measures 
were taken into account.  
 
Example 1 (Allowance for clustering and secular trends): “A generalised linear mixed model was used for 
categorical outcomes, and a linear mixed model was used for continuous outcomes, adjusting for age, gender, 
ethnicity and school terms (i.e., secular trend). The cluster effect by school and correlation between repeated 
measurements on the same child over time were taken into account in the multilevel analysis.” [SBP Trial] 
 
Example 2 (Cluster level analysis): The primary outcome (diarrhoeal prevalence) will be calculated for each cell in 
the stepped wedge design by aggregating over all individuals surveyed in each village during each time period. 
Estimation of intervention effects will be obtained from a linear regression of the logarithm of the village-
aggregated prevalence adjusting for seasonal effects and incorporating village as a fixed effect. The intervention 
effect coefficient will be exponentiated to produce an estimated relative reduction (with 95% CIs) in the overall 
prevalence of diarrhoea in the intervention periods (post-RBF) compared with control periods (piped but 
unfiltered water). This analysis model controls for both clustering of individuals within villages and for repeated 
assessments of villages over time... We will use multiple-imputation to impute missing outcomes at the individual 
person level which will then be aggregated for the village-level analyses.” [Riverbank Filtration Trial] 
 
Example 3 (Intention-to-treat analysis): “For the “intention-to-treat” analysis an indicator of whether an 
observation occurred pre- or post-randomisation was included in the regression model. To allow for delays in 
implementation a separate “per protocol” analysis was performed with the observations now placed into one of 
the three categories: “pre-randomisation”, “post-randomisation but pre-implementation” and “post-
implementation…” [FIT Trial] 
 
Explanation: The statistical methodology should be clearly reported to allow replication. Where possible it can be 
helpful to provide a reference to the statistical methodology used. In a SW-CRT, clusters are randomised to 
sequentially initiate the intervention. Observations collected under the control condition are therefore, on average, 
from an earlier calendar time than observations collected under the intervention condition. Changes external to the 
trial may create underlying secular trends. Likewise participants, if repeatedly measured over the duration of the 
study, may get sicker or recover over time. This means that time is a potential confounder. Analysis of a SW-CRT 
should adjust for time effects [Hussey 2007] irrespective of their statistical significance; failure to do so risks biasing 
the estimate of the intervention effect, which could lead to declaring an intervention effective when it is ineffective 
or ineffective when it is effective [Hemming 2017]. It is therefore essential to report if and how time effects were 
allowed for. If time is measured continuously, time can be modelled parametrically; if time is measured discreetly 
then time can be modelled categorically. Furthermore, SW-CRTs typically include only a small number of clusters 
[Martin 2016] and so pre-specification of important prognostic factors to use in a fully adjusted analysis (in 
mitigation of the likelihood of imbalance due to sampling variation) might also be undertaken [Senn 1994]. 
In a parallel CRT, randomisation at the level of the cluster needs to be allowed for at the analysis stage (unless 
cluster level data are being analysed). In a SW-CRT, as clusters (and possibly individuals) are repeatedly measured 
over time, there may be some reduction in the strength of correlation between measurements within the same 
cluster over time [Hooper 2016]. Failure to appropriately model the correlation structure can lead to incorrect 
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estimation of the precision of treatment effects [Thompson 2017]. It is therefore important to clearly describe the 
correlation structure used in the analysis.  
The analysis should also describe how deviations from the randomisation schedule were accommodated (Example 
3).  A more detailed consideration of this point is given under Item 16 (numbers analysed)In the context of a parallel 
design, an intention-to-treat analysis is defined as an analysis according to allocated group; the analogous definition 
in a SW-CRT is an analysis which treats all observations taken after the allocated cross-over date as exposed to the 
intervention. .  
Item 12b: Additional sStatistical methods 
Standard CONSORT item: Methods for additional analyses, such as subgroup analyses and adjusted analyses. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Methods for additional analyses, such as subgroup 
analyses and adjusted analyses. 
 
No modification suggested. 
 
Example (Time varying effect of intervention): “Furthermore, a delayed intervention effect of the CCs (Case 
Conference i.e. intervention) is assumed because the nurses need time to implement the procedure. Thus, the 
duration of the intervention in months must be considered.” [FallDem Trial] 
 
Explanation: SW-CRTs, like other trial designs, will commonly investigate subgroup differences and may perform 
adjusted analyses. In trials with a small number of clusters, investigating sensitivity to model assumptions will be 
important [Taljaard 2016].  
Of some importance in a SW-CRT is time by treatment interactions. Treatment by time interactions are treatment 
effects which change as the study progresses (not to be confused with secular changes which represent changes in 
the outcome under the control condition– Table 2 Key concept 1). These changing treatment effects are important 
,because  since observations contributing to the analysis will comprise a mixture of times since roll-out of the 
intervention. FInterventions delivered at a single occasion (and not repeated to ensure it creates a permanent effect) 
might have an impact which changes with increasing time since roll-out (for example, the effect of the intervention 
might be quite large immediately after roll-out and then its impact might start to wane). If interventions are refined 
over time then their effect will also change over the duration of the study. Few trials if any have clearly investigated 
these time by treatment interactions [Davey 2015; Martin 2017], although many interventions have been assessed 
as being at risk of time by treatmentintervention interactions [Davey 2015]. The example above makes an 
acknowledgement of the possibility of a delayed effect, although gives limited detail as to how it will be investigated.  
Of particular interest in a SW-CRT might be whether the effect of the intervention has a delayed effect (perhaps 
because its anticipated effect is not expected to materialise immediately (i.e. a lag effect); or if the intervention 
effect varies by time since exposure (e.g. an effect that decays over time or an effect that improves over time), 
perhaps because the effect of the intervention might be expected to wane with increasing time since exposure, 
particularly so in educational type interventions [Hughes 2015]; or perhaps due to the intervention being refined 
over the course of the roll-out.  
Also of interest might be whether the effect of the treatment varies between sequences, perhaps because 
participants get sicker (or recover) with longer duration in the control condition and the treatment is not anticipated 
to have the same effect in sicker participants [Copas 2015].  
Results: PParticipant flow  
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Item 13a: Participant flow 
Standard CONSORT item: For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome. 
CONSORT cluster extension: For each group, the numbers of clusters that were randomly assigned, received 
intended treatment, and were analysed for the primary outcome. 
Extension for stepped-wedge trialsExtension for SW-CRTs: For each treatment condition or allocated sequence, 
the numbers of clusters and participants who were assessed for eligibility, were randomly assigned, received 
intended treatments and were analysed for the primary outcome (Figure 3).  
 
Item 13b: Participant attrition Participant flow 
Standard CONSORT item: For each group, losses and exclusions after randomisation, together with reasons 
CONSORT cluster extension: For each group, losses and exclusions for both clusters and individual cluster 
members. 
Extension for  SW-CRTsstepped-wedge trial: For each treatment condition or allocated sequence, losses and 
exclusions for both clusters and participants with reasons. 
 
Example Flow chart by treatment condition and sequence (cross-sectional design): Supplementary Figure S2 
(Long-live Mothers Trial) 
 
 
Explanation: Information on the number of clusters and participants who were assessed for eligibility and outcomes 
along with the number of losses and exclusions (i.e. withdrawals) allows the reader to assess the risk of differential 
inclusion and attrition.  
Any flow chart should allow the reader to examine the nature of any differential inclusion and attrition by allocated 
sequence, treatment condition, and over time (see Example Figure S2). Because there are many different types of 
SW-CRTs there is unlikely to be one flow-chart that will be applicable for all SW-CRTs. How the flow chart is 
constructed will depend on how many sequences and clusters there are, whether participants contribute repeated 
measures, and whether participants can join and leave the study. This information could be presented by allocated 
sequence but might also be presented by treatment conditions.  
Including time periods in the flow chart is important to allow for assessment of differential participation over time. 
When different participants are sampled in each period, each participant will, in theory, be exposed to either the 
intervention or control condition. In this case, summarising the number of participants by treatment condition is 
possible. Where the same participant contributes multiple measurements, each participant may provide 
measurements under both intervention and control conditions. In this case, summarising the number of participants 
by allocated sequence, along with the average number of measurements contributed by each participant, is more 
appropriate.  
Reporting the number of clusters and participants approached, eligible and included along with the reasons for non-
participation is important to allow an assessment of study generalizability, and perhaps even more importantly, of 
biases due to differential participation between treatment conditions (or sequences). For example, in a parallel CRT 
without blinding of participants to treatment condition at the time of recruitment, a higher rate of consent among 
those recruited to the intervention condition can indicate recruitment bias [Caille 2016]. Information on reasons as 
to why participants or clusters are not included allows a reader to assess the appropriateness of exclusions.  
Results: Recruitment  
Item 14a: Recruitment  
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Standard CONSORT item: Dates defining the periods of recruitment and follow-up. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Dates defining the steps, initiation of intervention and 
deviations from planned dates. Dates defining recruitment and follow-up for participants. 
 
Example 1 (Step dates): “Twenty-two villages received the intervention in the second period (April-June 2011), 36 
in the third period (September-November 2011), 35 in the fourth period (April-June 2012), and 35 in the fifth 
period (September-November 2012).” [DAVE Trial] 
 
Example 2 (Deviations from planned dates): “There were 60 study wards in the 16 randomised hospitals, of which 
33 (22 ACE and 11 ITU) in 13 hospitals went on to implement the intervention, with a mean (SD) delay in 
implementation of 5 (4) months …and a mean (SD) duration of implementation of 12 (7) months. Eight wards 
began implementation very late, and for these the end of the trial was extended to December 31st 2009 to 
ensure that they had a year of data collection post-implementation.” [FIT Trial] 
 
Explanation: Dates defining periods of recruitment of participants can be reported where appropriate; in some 
designs these dates will be at the beginning of the study before any cross-over of clusters occurs; in other designs 
recruitment will be continuous throughout the study. In some studies there will be no direct participant recruitment, 
but identification of data from participants from routine data sources. 
Reporting of other key dates are also important in a SW-CRT. These dates include the dates defining when the study 
was undertaken and dates defining the steps. Dates defining the start and end of the roll-out phase, as well as the 
dates of the steps are useful to demonstrate if the trial was implemented as planned (Example 1). Dates should be 
presented so that they can be easily related to the planned timing of the steps as described in Item 3a. Reporting 
deviations from planned dates is particularly important in the SW-CRT as they demonstrate deviations from the 
randomised schedule (Example 2).  
Dates defining implementation of interventions will allow assessment of when the intervention is fully implemented 
in each cluster. Dates defining actual implementation of the intervention should be specified. The realised time for 
an intervention to become fully implemented may differ from that which was planned. This allows assessment of 
whether all observations collected under the intervention condition were fully exposed to the intervention; it also 
allows assessment of whether any observations collected under the control condition were likely contaminated by 
the intervention. Reporting dates also allows inferences about external influences which may have affected secular 
trends.  
Item 14b: Recruitment 
Standard CONSORT item: Why the trial ended or was stopped. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Why the trial ended or was stopped. 
No modification suggested.   
 
Explanation: Readers are referred to the CONSORT statement and the extension to the CONSORT statement for 
examples and explanation [Schulz 2010, Campbell 2012].  
 
Results: Baseline data 
Item 15: Baseline data 
Standard CONSORT: A table showing baseline demographic and clinical characteristics for each group. 
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CONSORT cluster extension: Baseline characteristics for the individual and cluster levels as applicable for each 
group. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Baseline characteristics for the individual and cluster 
levels as applicable for each treatment condition or allocated sequence.  
 
Example 1 Baseline table by treatment condition (cross-sectional design): Supplementary Table S21 (DAVE Trial) 
Example 2 Baseline table by allocated sequence (open cohort design): Supplementary Table S32 (Depression 
Management Trial) 
 
Explanation: In a parallel CRT a summary of the cluster and participant level characteristics at baseline by treatment 
condition can allow assessment of the success of randomisation and provides a description of the included sample. 
In trials with post-randomisation recruitment, this table can allow an assessment of potential biases.  
The term “baseline” in a SW-CRT can be confusing because of the longitudinal nature of the design. We use the term 
“baseline characteristic” to mean a characteristic which was either measured before exposure to the control or 
intervention condition, or which is not expected to be influenced by the treatment conditions (e.g. age). In designs in 
which observations are made on different participants in each period, these baseline characteristics will often 
pertain to measurements made  just prior to the switch from control to intervention condition at that period (i.e. not 
at the start of the trial); whereas in designs where participants are repeatedly assessed, these characteristics might 
be measured prior to randomisation. Cluster level characteristics can often be measured prior to randomisation and 
are less likely to change over time.  
For SW-CRTs in which observations are made on different participants in each period, the summary of baseline 
characteristics could be presented by treatment condition or by allocated sequence. For example, the DAVE Trial, 
which measures different participants in each period, reports its baseline table by treatment condition (Table S21).  
For SW-CRTs in which the same participants are repeatedly assessed in each of the periods, the baseline 
characteristics of participants will normally be presented by allocated sequence rather than by treatment condition. 
This is because most participants will be observed first under the control and then intervention condition. The 
Depression Management Trial (Table S32) provides summary characteristics by allocated sequence.  
Results: Numbers analysed  
Item 16: Numbers analysed 
Standard CONSORT: For each group, number of participants (denominator) included in each analysis and whether 
the analysis was by original assigned groups. 
CONSORT cluster extension: For each group, number of clusters included in each analysis. 
Extension for stepped-wedge trialsExtension for SW-CRTs: The number of observations and clusters included in 
each analysis for each treatment condition and whether the analysis was according to the allocated schedule. 
 
Example 1 (Numbers by treatment condition): “A total of 5295 surgical procedures were carried out throughout 
the stepped wedge cluster RCT, that is, 2212 in control and 3083 (of which 2263 had the SSC performed) after 
implementation of the SSC (Surgical Safety Checklist). Patients (14.9%; 667/4475) underwent more than 1 
procedure. The control and SSC study steps included 1778 and 2033 unique patients, respectively.” [Surgical 
Checklist Trial] 
 
Example 2 (Intention-to-treat vs. per protocol): “The flow diagram shows there were 60 study wards in the 16 
randomised hospitals, of which 33 (22 ACE and 11 ITU) in 13 hospitals went on to implement the intervention… 
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For the primary outcome, intention-to-treat analysis was conducted for the 60 wards randomised into the 
intervention, and per-protocol analysis was performed for the 33 implementing wards…” [FIT Trial] 
 
Explanation: The number of observations by treatment condition should be reported for analyses of all outcomes 
(Example 1). For some outcomes this information will be included in a flow chart although not all flow charts for a 
SW-CRT will give an immediate summary of this information by treatment condition. When the same participants are 
repeatedly measured across the time periods, each participant will have been exposed to both treatment conditions 
and so this information can be reported either by giving the total number of observations (by treatment condition) 
or as the number of participants in the study and average number of assessments per participant under each 
treatment condition. Where different participants contribute to each measurement period, it might be useful to 
have information on the number of participants per cluster-period. Such information might be most easily reported 
in a diagram rather than in text (Figure 3).  
Sometimes clusters (and perhaps participants) will not receive the intervention condition as per the randomisation 
schedule (Example 2). In a parallel trial anThe intention-to-treat analysis performs the analysis according to the 
groups to which participants or clusters were originally assigned [Moher 2012]. In a SW-CRT this might be 
interpreted as analysis of treats clusters and participants treated as as exposed to the intervention according to the 
dates of the randomisation schedule (i.e. according to the planned dates of being considered exposed to 
intervention). In a SW-CRT, Tthe application of this principale would would mean that clusters are would be treated 
as exposed to the intervention if the observation comes from a time period post allocated cross-over date. When a 
SW-CRT has randomised clusters to actual dates of to transitioning from control to intervention, an intention-to-
treat analysis following this interpretation is logical.  
Alternatively, a SW-CRT might be considered as randomising the order that the clusters transition from control to 
intervention (although when there are multiple clusters per sequence, several clusters share the same rank-order). 
In this situation an intention-to-treat analysis might be interpreted as analysis of clusters and participants treated as 
exposed to the intervention according to the order of the randomisation schedule (i.e. according to the planned 
order of roll-out). The application of this principle would mean that clusters are treated as exposed to the 
intervention only after the intervention has been implemented roll-out in that cluster, provided the order of the 
allocation did not deviate from that planned.   
Providing information on the number of clusters (and participants) contributing to all the intention-to-treat and 
other analyses allows assessment of whether the analysis has been conducted with respect to the randomised cross-
over schedule – which might not be in strict accordance with any pre-specified dates; or to and not to the actual 
cross-over dates that may deviate from planned dates due to delays in implementation.  
Sometimes a cluster may drop out from some purposively collected outcome assessments, but still contribute data 
from routinely collected sources for other outcome variables. If the numbers included in secondary analyses differ 
from those included in primary analyses, information on differential attrition (or participation) across clusters or 
periods can be provided in the text (similar to information depicted in the flow chart for the primary outcome 
(Figure 3). 
Results: Outcomes and estimation  
Item 17a: Outcomes and estimation 
Standard CONSORT item: For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision (such as 95% confidence interval). 
CONSORT cluster extension: Results at the individual or cluster level as applicable and a coefficient of intra-cluster 
correlation (ICC or k) for each primary outcome. 
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Extension for stepped-wedge trialsExtension for SW-CRTs: For each primary and secondary outcome, results for 
each treatment condition, and the estimated effect size and its precision (such as 95% confidence interval); any 
correlations  and time effects estimated in the analysis.   
 
Example 1 (Time adjusted treatment effect): “A total of 321 (10.8%) unexposed patients were started on either 
antihypertensives or statins, and 577 (19.7%) exposed patients. The time-adjusted mean difference in proportion 
of patients initiating either treatment was 15.5% (95% CI = 3.9 to 27.1).” [Targeted Case Finding Trial] 
 
Example 2 (Secular trend): Supplementary Figure S32 [FIT Trial] 
 
Example 3 (Correlations): “The ICC in the time-adjusted analysis for initiation of either treatment was 0.014 (95% 
CI = 0.005 to 0.038).” [Targeted Case Finding Trial] 
 
Explanation: A summary of the findings for each primary and secondary outcome should be provided for each 
treatment condition. This will allow a description of the severity or prevalence of the outcome in the sample 
(Example 1). In addition, reporting of results by treatment condition allows estimation of an unadjusted effect of the 
intervention for comparison with a time adjusted effect (as in Example 1).  
Treatment effects should be reported along with 95% Confidence Intervals (CI). A SW-CRT which does not adjust for 
time is analogous to a simple uncontrolled before-and-after experiment; therefore, it should be clearly reported if 
the primary and secondary outcomes were adjusted for time (Example 1). To allow an understanding of the potential 
impact of secular trends it can be helpful to describe the secular trend – either in a figure or as regression 
coefficients. Ideally this should be done by calendar time and should represent the trend in the clusters yet to be 
exposed to the intervention (Example 2: Figure S32). In some SW-CRTs participants will be recruited at the very 
beginning of the trial and measured repeatedly. In chronic conditions these participants may naturally regress over 
the duration of the study; in acute conditions they may recover. Whilst not a secular trend per se, such effects still 
may lead to confounding of the intervention effect with time and so time should be adjusted for.  
Reporting any estimated coefficients of intra-cluster correlation (ICCs) can be informative for the planning of future 
trials (Example 3) [Hooper 2016]. Correlation structures are more complex than in a parallel cluster trials conducted 
at a single cross-section in time; therefore, analysis (and reporting) of a single measure of correlation such as the ICC 
might not be sufficient [Kasza 2017]. Relevant correlation coefficients  Types of correlations might include 
correlations between observations in the same cluster and same time period (within-period ICC); correlations 
between observations in the same cluster but different time periods (between-period ICC), as well as between-
period and within-period correlations on the same individual [Hooper 2016]. It is important to be explicit about the 
types of correlations being reported [Martin 2016b]. Reporting of variance components is an alternative to intra-
cluster correlations, particularly for non-continuous outcomes [Hayes 1999]. When intra-cluster correlations are 
reported for binary outcomes, clearly indicating the scale (e.g. proportions or logistic scale) can help interpretation 
[Eldridge 2009].  
Types of correlations might include correlations between observations in the same cluster and same time period 
(within-period ICC); correlations between observations in the same cluster but different time periods (between-
period ICC), as well as between-period and within-period correlations on the same individual. It is important to be 
explicit about the type of correlations being reported [Martin 2016b]. 
Results: Outcomes and estimation  
Item 17b: Binary outcomesOutcomes and estimation 
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Standard CONSORT item: For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: For binary outcomes, presentation of both absolute 
and relative effect sizes is recommended. 
No modification suggested. 
 
Explanation: In addition to reporting a relative measure of the effect of the intervention it can be helpful to report an 
absolute measure of the effect: while absolute measures of effects are more easily understood, relative measures of 
effects are often more stable across different populations [Ukoumunne 2008]. 
While reporting relative and absolute measures of effects is recommended, further methodological work is required 
to determine optimal methods of analysis that yield such estimates. Current approaches include fitting two separate 
models (for example a binomial model with log link to report the relative risks; and a binomial model with an identity 
link to report a risk difference) or by fitting one model and using a transformation to report the other measure of 
treatment effect [Pedroza 2016].  
Model based methods for achieving estimates on both scales have been investigated in parallel CRTs in which the 
model is unadjusted for confounders [Ukoumunne 2008]; and. Although others have evaluated the performance of 
these models when covariate adjustment is required [Pedroza 2016].In SW-CRTs these models would further need to 
adjust for the confounding effect of time.  
Results: Ancillary analyses   
Item 18: Ancillary analyses   
Standard CONSORT item: Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory. 
No modification suggested.  
 
Explanation: There are several analyses that can be considered to examine deviation from model assumptions, for 
example, variations in secular trends across groups of clusters [Hemming 2017]; interactions of the intervention 
effect with sequence; and whether the effect of the intervention might change with increasing duration of exposure 
(Item 12b). In the reporting of these ancillary analyses, any limitations due to the assumptions made should be 
noted.  
Results: Harms  
Item 19: Harms 
Standard CONSORT item: All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms). 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Important harms or unintended effects in each 
treatment condition (for specific guidance see CONSORT for harms). 
 
Explanation: Readers are referred to the CONSORT statement and the extension to the CONSORT statement for 
examples and explanation [Schulz 2010; Campbell 2012].  
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Discussion:  
Item 20: Limitations 
Standard CONSORT item: Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses. 
No modification suggested. 
 
Explanation: Estimated intervention effects from a SW-CRT will almost always be model-based estimates adjusting 
for time. There is a host of different models which can be used, but all make some assumptions. The assumptions 
made and potential limitations should be reflected on.  
Item 21: Discussion 
Standard CONSORT item: Generalisability (external validity, applicability) of the trial findings. 
CONSORT cluster extension: Generalisability to clusters and/or individual participants (as relevant) 
Extension for stepped-wedge trialsExtension for SW-CRTs: Generalisability (external validity, applicability) of the 
trial findings. Generalisability to clusters and/or individual participants (as relevant).  
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010, Campbell 2012].  
 
Item 22: Interpretation 
Standard CONSORT item: Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence. 
CONSORT cluster extension: No modification suggested 
Extension for stepped-wedge trialsExtension for SW-CRTs: Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant evidence. 
No modification suggested. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Other information  
Item 23: Trial registration 
Standard CONSORT item: Registration number and name of trial registry. 
CONSORT cluster extension: No modification suggested.  
Extension for stepped-wedge trialsExtension for SW-CRTs: Registration number and name of trial registry. 
No modification suggested.  
 
Explanation: The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial “as any research 
project that prospectively assigns people or a group of people to an intervention, with or without concurrent 
comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and 
a health outcome” [ICMJE]. The ICMJE states that all medical journal editors should require clinical trials to be 
registered (prior to the first patient enrolment) as a condition of publication. SW-CRTs of health related 
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interventions meet the ICMJE’s definition of a clinical trial and so therefore should wherever possible be registered 
as a clinical trial prior to the study start date.  
Reporting the name of the trial registry and the unique trial registration number facilitates crosschecking with the 
associated registry entry and allows assessment of whether there are any important changes to the trial design, and 
the potential for any bias (such as outcome reporting bias). Further, reporting details of the trial registration 
facilitates linking of multiple publications from the same trial, which is of particular importance for systematic 
reviews. If the trial has not been registered, this should be stated along with the reason. 
Studies examining trial registration rates have found that a large percentage of trials are not registered (e.g. 28% - 
44% [Azar 2015; Killeen 2014; Wetering 2012]). Further, in the trials that are registered, not all report the 
registration details in the trial publication, and not all are prospectively registered. A recent review that examined 
registration of SW-CRTS found that only 50% of SW-CRTs were prospectively registered [Taljaard 2017].   
Item 24: Trial protocol 
Standard CONSORT item: Where the full trial protocol can be accessed, if available. 
CONSORT cluster extension: No modification suggested 
Extension for stepped-wedge trialsExtension for SW-CRTs: Where the full trial protocol can be accessed, if 
available. 
No modification suggested. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010; Campbell 2012].  
 
Item 25: Funding 
Standard CONSORT item: Sources of funding and other support (such as supply of drugs), role of funders. 
CONSORT cluster extension: No modification suggested. 
Extension for stepped-wedge trialsExtension for SW-CRTs: Sources of funding and other support (such as supply of 
drugs), role of funders. 
No modification suggested. 
 
Readers are referred to the CONSORT statement and the extension to the CONSORT statement for examples and 
explanation [Schulz 2010, Campbell 2012].  
 
Item 26: Research Ethics Review 
Standard CONSORT item: Not included.  
CONSORT cluster extension: Not included  
Extension for stepped-wedge trialsExtension for SW-CRTs: Whether the study was approved by a research ethics 
committee, with identification of the review committee(s). Justification for any waiver or modification of 
informed consent requirements.  
 
Example 1 (Full review): “The study received ethical approval from the Sport and Health Sciences Ethics 
Committee at the University of Exeter (February 2011).” [DAVE Trial Protocol] 
Example 2 (Waiver of consent): “This study was reviewed by the Regional Committee for Medical and Health 
Research Ethics (Ref: 2009/561), which advised that use of routinely collected anonymized patient data is clinical 
service improvement and thus no further approval or patient consent is required.”[Surgical Checklist Trial] 
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Explanation: The original CONSORT statement did not include an item on research ethics approval because it is an 
existing International Committee of Medical Journal Editors requirement that research “involving human data” 
should indicate whether the research was reviewed by a research ethics committee [ICMJE]. However, a systematic 
review found that only 75% of SW-CRTs reported review by a research ethics committee, possibly due to the 
classification of such studies, by some researchers, as service development or quality improvement. To encourage 
clear reporting about research ethics review of SW-CRTs we have therefore included this as a new item. This is 
consistent with the recent extension to the CONSORT statement for pilot studies, which also included this as a new 
item [Eldridge 2016]. An application number or reference number of the ethical approval should also be reported. If 
a study is deemed exempt from review by a research ethics committee, this should be reported together with a clear 
justification for the exemption from review.  
Conclusions  
The SW-CRT offers an exciting new opportunity to rigorously examine the effects of implementation, policy and 
service delivery interventions. The design is appealing in many respects, but also provides many challenges. It has 
noteworthy risks for biases including bias due to temporal trends and within-cluster contamination, as well as 
methodological complexities such as changes in correlation structures over time. Furthermore, perhaps because the 
design is being used in situations where researchers are not familiar with standards for reporting or conduct, SW-
CRTs have been noted to be particularly prone to inadequacies of ethical reporting, including research ethics review 
and (in common with many cluster trials) identification of research participants. This extension of the CONSORT 
statement for SW-CRTs encourages researchers to reflect on the unique aspects of the SW-CRT and improve the 
clarity of reporting.  
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